adalimumab vs infliximab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Crohn's Disease
Shared mechanism: TNF-alpha · full Crohn's Disease pipeline
adalimumab · Humira
Marketed by AbbVie and partners
NCT00055497 · Phase 3 · completed
Design meets top-tier criteria (randomized, quadruple-blind, placebo-controlled, hard clinical endpoint), but the randomized comparison population was very small (only 55 total randomized participants across 3 arms) and the two primary analysis methods gave discordant significance results (NRI missed, LOCF met), which per the definitions caps this at moderate under both the underpowered-n and mixed/unclear-primary-result tests.
Next expected readout: June 2027 · NCT06045754 (registry estimate)
Reported efficacy
Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4: Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4 (Week 4): Double-Blind Period, Weeks 0 to 4: Placebo 6.8% vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg 37.3%; p=<0.001 (Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg) (met)
Result source: NCT02499783
infliximab · Remicade
Marketed by Johnson & Johnson
NCT00094458 · Phase 3 · completed
This meets the 'strong' test: randomized, triple-blinded (participant/investigator/outcomes assessor), active-comparator (not merely placebo) design, adequately powered (n=508), a primary endpoint that is a hard clinical measure (corticosteroid-free clinical remission via CDAI), and the primary comparisons reached statistical significance in the favorable direction for the key comparisons (combo vs AZA and IFX vs AZA).
Next expected readout: November 2026 · NCT05906576 (registry estimate)
Reported efficacy
Percentage of Participants With Corticosteriod-free Clinical Remission (Week 26): Percentage of Participants With Corticosteriod-free Clinical Remission (Week 26): Azathioprine + Placebo 30.0% vs Infliximab + Placebo 44.4% vs Infliximab + Azathioprine 56.8%; p=<0.001 (Azathioprine + Placebo vs Infliximab + Azathioprine), p=0.006 (Azathioprine + Placebo vs Infliximab + Placebo), p=0.022 (Infliximab + Placebo vs Infliximab + Azathioprine) (met)
Result source: NCT00094458
Results for Crohn's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab | infliximab |
|---|---|---|
| Clinical remission (induction) | 37.3% vs 6.8%+30.5 vs placeboNCT024997831 other result
| 47.3% vs 34.1%vs Azathioprine + PlaceboNCT000944585 other results
|
| Endoscopic response (induction) | —Trial running · NCT05040464 | —Not posted · NCT00004941 |
| Clinical remission (maintenance) | 47.4% vs 33.3%+14.1 vs placeboNCT0005549711 other results
| 66% vs 54.7%vs Azathioprine + PlaceboNCT000944587 other results
|
| Endoscopic response (maintenance) | —Trial running · NCT05040464 | —Not posted · NCT00004941 |
Clinical remission (induction)
- adalimumab
- 37.3% vs 6.8%+30.5 vs placeboNCT02499783
1 other result
- 46.9% vs 27.7% NCT00348283
- infliximab
- 47.3% vs 34.1%vs Azathioprine + PlaceboNCT00094458
5 other results
- 59.8% vs 34.1% NCT00094458
- 49.1% vs 27.6% NCT00094458
- 52.1% vs 27.6% NCT00094458
- 32.5% vs 17.6% NCT00094458
- 36.7% vs 17.6% NCT00094458
Endoscopic response (induction)
- adalimumab
- —Trial running · NCT05040464
- infliximab
- —Not posted · NCT00004941
Clinical remission (maintenance)
- adalimumab
- 47.4% vs 33.3%+14.1 vs placeboNCT00055497
11 other results
- 66.7% vs 33.3% NCT00055497
- 78.9% vs 44.4% NCT00055497
- 83.3% vs 44.4% NCT00055497
- 38.1% vs 9.1% NCT00445432
- 36.3% vs 38.9% NCT00055497
- 40.2% vs 38.9% NCT00055497
- 32.8% vs 9.2% NCT00348283
- 57.9% vs 38.9% NCT00055497
- 94.4% vs 38.9% NCT00055497
- 57.9% vs 38.9% NCT00055497
- 94.4% vs 38.9% NCT00055497
- infliximab
- 66% vs 54.7%vs Azathioprine + PlaceboNCT00094458
7 other results
- 74.1% vs 54.7% NCT00094458
- 72.2% vs 58.7% NCT00094458
- 73.1% vs 58.7% NCT00094458
- 66% vs 61.3% NCT00094458
- 69.4% vs 61.3% NCT00094458
- 47.9% vs 31.8% NCT00094458
- 60.4% vs 31.8% NCT00094458
Endoscopic response (maintenance)
- adalimumab
- —Trial running · NCT05040464
- infliximab
- —Not posted · NCT00004941
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
5 other shared endpoints and safety
Coverage. adalimumab: 9 of 9 rows · infliximab: 9 of 9 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | adalimumab Rows use multiple source trials | infliximab Rows use multiple source trials |
|---|---|---|
| CDAI responder rate · % of participants Induction | 67.6% (n=102) vs 27.2% (n=103) placebo @ 4wk160/80 mga,b NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3 | 69.2% (n=169) vs 39.4% (n=170) Azathioprine + Placebo @ 10wkc,a,b NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 show 1 more dose55.6% (n=169) vs 39.4% (n=170) Azathioprine + Placebo @ 10wk NCT00094458 · Phase 3 · Crohn's Disease · phase 3 |
| CDAI absolute change · score No placebo or comparator arm | -173.55 score @ 36wkd NCT00686374 · Phase 3 · monotherapy | 139 score @ 36wkd NCT00805766 · Phase 3 · monotherapy |
| Clinical Remission responder rate · % of participants | 29.7% (n=64) vs 4.6% (n=65) placebo*e NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 19 Subjects as posted | 60.4% (n=169) vs 33.5% (n=170) Azathioprine + Placebo @ 18wkc,e NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 show 1 more dose49.7% (n=169) vs 33.5% (n=170) Azathioprine + Placebo @ 18wk NCT00094458 · Phase 3 · Crohn's Disease · phase 3 |
| Clinical Remission responder rate · % of participants No placebo or comparator arm | 80% (n=65) @ 36wk*d NCT00686374 · Phase 3 · monotherapy · converted to % from 52 Participants as posted 1 other source trial39.3% (n=28) @ 36wk80 mg NCT01958827 · Phase 3 · monotherapy | 59.3% (n=39) @ 36wkd NCT00805766 · Phase 3 · monotherapy |
| PCDAI absolute change · score No placebo or comparator arm | -46.25 score @ 384wkf,g NCT00686374 · Phase 3 · monotherapy | -28.33 score @ 54wkf,g NCT01580670 · Phase 3 · monotherapy |
| Dropout rate | —40 mg every other weekh NCT00055497 · Phase 3 show 34 more results15.8%40 mg every other week NCT00055497 · Phase 3 11.1%40 mg every week NCT00055497 · Phase 3 —40 mg every week NCT00055497 · Phase 3 40.7%40 mg NCT00055497 · Phase 3 —160/80 mg NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3 48.5% NCT00195715 · Phase 3 16.9%40 mg every other week or every week NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3 4.4% NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3 6.8%Induction: Higher Induction Dose NCT02065570 · Phase 3 · monotherapy 6.8%Induction: Standard Induction Dose NCT02065570 · Phase 3 · monotherapy —Maintenance: Clinically Adjusted ( NCT02065570 · Phase 3 · monotherapy —Maintenance: Therapeutic Drug Mana NCT02065570 · Phase 3 · monotherapy —Maintenance: Therapeutic Drug Moni NCT02065570 · Phase 3 · monotherapy 21.4% NCT02185014 · Phase 3 · monotherapy 61% NCT00686374 · Phase 3 · monotherapy —40 mg or 20 mg every other week NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 —20 mg or 10 mg every other week NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 60%40 mg Eow NCT00445432 · Phase 2/3 · monotherapy 34.4%40 mg Eow NCT00445432 · Phase 2/3 · monotherapy 3%160 mg/80 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —160 mg/80 mg + 40/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —160 mg/80 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —80/40 mg + 40/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 5.9%80 mg/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 35.7%80 mg NCT01958827 · Phase 3 · monotherapy 16.4%40 mg every other week NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3 70.9%300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral) NCT02764762 · Phase 4 · registry result, not featured evidence · combination 36% NCT02148718 · Phase 4 · registry result, not featured evidence 26.7%Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence 26.7%Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence | 28.4%Infliximab + Azathioprinei NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 show 9 more results34.3%Infliximab + Placebo NCT00094458 · Phase 3 · Crohn's Disease · phase 3 —W30-Infliximab + Azathioprine NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 —W30-Infliximab + Placebo NCT00094458 · Phase 3 · Crohn's Disease · phase 3 —W50-Infliximab + Azathioprine NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 —W50-Infliximab + Placebo NCT00094458 · Phase 3 · Crohn's Disease · phase 3 0% NCT01580670 · Phase 3 · monotherapy 13.3% NCT00805766 · Phase 3 · monotherapy 18.2% NCT00688636 · Phase 4 · registry result, not featured evidence 50% NCT00791557 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | —40 mg every other weekh NCT00055497 · Phase 3 show 34 more results5.3%40 mg every other week NCT00055497 · Phase 3 5.6%40 mg every week NCT00055497 · Phase 3 —40 mg every week NCT00055497 · Phase 3 12.7%40 mg NCT00055497 · Phase 3 —160/80 mg NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3 15.7% NCT00195715 · Phase 3 6%40 mg every other week or every week NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3 1.5% NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3 3.9%Induction: Higher Induction Dose NCT02065570 · Phase 3 · monotherapy 2.4%Induction: Standard Induction Dose NCT02065570 · Phase 3 · monotherapy —Maintenance: Clinically Adjusted ( NCT02065570 · Phase 3 · monotherapy —Maintenance: Therapeutic Drug Mana NCT02065570 · Phase 3 · monotherapy —Maintenance: Therapeutic Drug Moni NCT02065570 · Phase 3 · monotherapy 7.1% NCT02185014 · Phase 3 · monotherapy 8% NCT00686374 · Phase 3 · monotherapy —40 mg or 20 mg every other week NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 —20 mg or 10 mg every other week NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 4%40 mg Eow NCT00445432 · Phase 2/3 · monotherapy 21.9%40 mg Eow NCT00445432 · Phase 2/3 · monotherapy 3%160 mg/80 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —160 mg/80 mg + 40/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —160 mg/80 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —80/40 mg + 40/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 5.9%80 mg/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 10.7%80 mg NCT01958827 · Phase 3 · monotherapy 10.9%40 mg every other week NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3 16.4%300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral) NCT02764762 · Phase 4 · registry result, not featured evidence · combination — NCT02148718 · Phase 4 · registry result, not featured evidence 20%Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence 20%Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence | 16.6%Infliximab + Azathioprinei NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 show 9 more results11.8%Infliximab + Placebo NCT00094458 · Phase 3 · Crohn's Disease · phase 3 —W30-Infliximab + Azathioprine NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 —W30-Infliximab + Placebo NCT00094458 · Phase 3 · Crohn's Disease · phase 3 —W50-Infliximab + Azathioprine NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 —W50-Infliximab + Placebo NCT00094458 · Phase 3 · Crohn's Disease · phase 3 — NCT01580670 · Phase 3 · monotherapy 2.2% NCT00805766 · Phase 3 · monotherapy 18.2% NCT00688636 · Phase 4 · registry result, not featured evidence 50% NCT00791557 · Phase na · registry result, not featured evidence |
| Serious AEs | 5.3%40 mg every other weekh NCT00055497 · Phase 3 show 34 more results—40 mg every other week NCT00055497 · Phase 3 —40 mg every week NCT00055497 · Phase 3 0%40 mg every week NCT00055497 · Phase 3 16.7%40 mg NCT00055497 · Phase 3 2%160/80 mg NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3 38.1% NCT00195715 · Phase 3 —40 mg every other week or every week NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3 14.8% NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3 4.5%Induction: Higher Induction Dose NCT02065570 · Phase 3 · monotherapy 4.9%Induction: Standard Induction Dose NCT02065570 · Phase 3 · monotherapy 4.6%Maintenance: Clinically Adjusted ( NCT02065570 · Phase 3 · monotherapy 6.4%Maintenance: Therapeutic Drug Mana NCT02065570 · Phase 3 · monotherapy —Maintenance: Therapeutic Drug Moni NCT02065570 · Phase 3 · monotherapy 10.7% NCT02185014 · Phase 3 · monotherapy 48% NCT00686374 · Phase 3 · monotherapy 23.7%40 mg or 20 mg every other week NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 20%20 mg or 10 mg every other week NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 8%40 mg Eow NCT00445432 · Phase 2/3 · monotherapy 40.6%40 mg Eow NCT00445432 · Phase 2/3 · monotherapy —160 mg/80 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —160 mg/80 mg + 40/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —160 mg/80 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —80/40 mg + 40/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —80 mg/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 28.6%80 mg NCT01958827 · Phase 3 · monotherapy —40 mg every other week NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3 10.9%300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral) NCT02764762 · Phase 4 · registry result, not featured evidence · combination 2.3% NCT02148718 · Phase 4 · registry result, not featured evidence —Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence 6.7%Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence 7.7%Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence 6.7%Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence 14.3%Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence | —Infliximab + Azathioprinei NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 show 9 more results—Infliximab + Placebo NCT00094458 · Phase 3 · Crohn's Disease · phase 3 14%W30-Infliximab + Azathioprine NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 16%W30-Infliximab + Placebo NCT00094458 · Phase 3 · Crohn's Disease · phase 3 1.9%W50-Infliximab + Azathioprine NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 15.5%W50-Infliximab + Placebo NCT00094458 · Phase 3 · Crohn's Disease · phase 3 14.3% NCT01580670 · Phase 3 · monotherapy — NCT00805766 · Phase 3 · monotherapy 9.1% NCT00688636 · Phase 4 · registry result, not featured evidence 0% NCT00791557 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | 40 mg every other weekh nasopharyngitis 26.3% (placebo 38.9%) crohn's disease aggravated 21.1% (placebo 27.8%) sinusitis 21.1% (placebo 5.6%) NCT00055497 · Phase 3 show 28 more results40 mg every week crohn's disease aggravated 11.1% (placebo 27.8%) dizziness (excl vertigo) 11.1% (placebo 5.6%) nasopharyngitis 11.1% (placebo 38.9%) NCT00055497 · Phase 3 40 mg crohn's disease aggravated 17.6% (placebo 27.8%) nasopharyngitis 16.7% (placebo 38.9%) headache 14% (placebo 11.1%) NCT00055497 · Phase 3 160/80 mg white blood cell count decreased 5.9% (placebo 1%) cough 4.9% (placebo 0%) dizziness 3.9% (placebo 0%) NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3 40 mg every other week or every week headache 18.9% nasopharyngitis 14.4% arthralgia 7.6% NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3 crohn's disease 23.4% (placebo 29.2%) headache 14.1% (placebo 9.2%) nasopharyngitis 14.1% (placebo 12.3%) NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3 viral upper respiratory tract infection 39% headache 37% upper respiratory tract infection 31% NCT00686374 · Phase 3 · monotherapy 40 mg or 20 mg every other week headache 17.2% crohn's disease 11.8% nausea 10.8% NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 20 mg or 10 mg every other week headache 21.1% crohn's disease 15.8% nasopharyngitis 11.6% NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 40 mg Eow nasopharyngitis 56% (placebo 12%) rhinorrhoea 16% (placebo 0%) adverse drug reaction 12% (placebo 4%) NCT00445432 · Phase 2/3 · monotherapy 40 mg Eow nasopharyngitis 71.9% (placebo 12%) adverse drug reaction 18.8% (placebo 4%) iron deficiency anaemia 18.8% (placebo 0%) NCT00445432 · Phase 2/3 · monotherapy 160 mg/80 mg + 40/40 mg adverse drug reaction 11.1% (placebo 4.3%) application site swelling 11.1% (placebo 0%) blood creatine phosphokinase (at investigator's discretion) 11.1% (placebo 0%) NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 160 mg/80 mg headache 9.1% (placebo 4.3%) upper respiratory tract infection 9.1% (placebo 4.3%) abdominal distension 6.1% (placebo 0%) NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 80/40 mg + 40/40 mg headache 16.7% (placebo 4.3%) abdominal distension 8.3% (placebo 0%) abdominal pain 8.3% (placebo 4.3%) NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 80 mg/40 mg injection site reaction 8.8% (placebo 8.7%) malaise 8.8% (placebo 0%) rhinorrhoea 8.8% (placebo 0%) NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 40 mg every other week crohn's disease 16.1% abdominal pain 7.6% injection site reaction 7.6% NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3 300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral) arthralgia 18.2% crohn's disease 16.4% nasopharyngitis 10.9% NCT02764762 · Phase 4 · registry result, not featured evidence · combination vomiting 7% abdominal mass 5.8% arthralgia 4.7% NCT02148718 · Phase 4 · registry result, not featured evidence Low Induction Dose leukopenia 20% pyrexia 13.3% arthralgia 6.7% NCT02015793 · Phase 2 · registry result, not featured evidence Low Induction Dose leukopenia 15.4% animal bite 7.7% aphthous stomatitis 7.7% NCT02015793 · Phase 2 · registry result, not featured evidence Standard Induction Dose alanine aminotransferase increased 13.3% aspartate aminotransferase increased 13.3% abdominal pain 6.7% NCT02015793 · Phase 2 · registry result, not featured evidence Standard Induction Dose mycobacterium tuberculosis complex test positive 14.3% aspartate aminotransferase increased 7.1% asthenia 7.1% NCT02015793 · Phase 2 · registry result, not featured evidence | i nausea 21.8% abdominal pain 13.4% fatigue 13.4% NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 show 6 more resultsabdominal pain 9.3% nasopharyngitis 8.3% crohn's disease 5.6% NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3 double stranded dna antibody positive 50% gastroenteritis 21.4% headache 21.4% NCT01580670 · Phase 3 · monotherapy infusion reaction 18.2% (placebo 7.7%) abcess 9.1% (placebo 7.7%) bronchitis 9.1% (placebo 0%) NCT00688636 · Phase 4 · registry result, not featured evidence bone marrow suppression 50% infection 50% infusion reaction 50% NCT00791557 · Phase na · registry result, not featured evidence |
Notes
- aPopulation context differs: prior_therapy differs (experienced versus none recorded).
- bAssessment timepoints differ: 4 weeks versus 10 weeks.
- cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- dPopulation context differs: age eligibility differs (includes children versus adolescents and adults).
- eThe assessment timepoint is not available for both results.
- fPopulation comparability has not been reviewed for both studies.
- gAssessment timepoints differ: 384 weeks versus 54 weeks.
- hPopulation comparability has not been reviewed for 24 of these studies.
- iPopulation comparability has not been reviewed for 4 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
adalimumab
show 11 more results
show 11 more results
show 6 more results
show 4 more results
show 1 more result
+ 55 further endpoints in the CSV export.
infliximab
show 3 more results
show 1 more result
show 1 more result
show 7 more results
show 5 more results
show 1 more result
show 1 more result
show 5 more results
show 1 more result
show 1 more result
show 13 more results
+ 7 further endpoints in the CSV export.
Ulcerative Colitis
Shared mechanism: TNF-alpha · full Ulcerative Colitis pipeline
adalimumab · Humira
Marketed by AbbVie and partners
NCT00385736 · Phase 3 · completed
Design is strong (randomized, quadruple-blind, placebo-controlled, n=576, hard endoscopic/clinical Mayo remission endpoint), but the primary endpoint result was discordant across the two pre-specified dose-vs-placebo comparisons: one significant, one not. A well-designed trial with a mixed result is capped at moderate rather than strong.
Next expected readout: September 2027 · NCT06257875 (registry estimate)
Reported efficacy
Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8; Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 52: Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8 (Week 8): Adalimumab 160/80/40 16.5% vs Placebo 9.3%; p=0.019 (Adalimumab 160/80/40 vs Placebo) (met)
Result source: NCT00408629
infliximab · Remicade
Marketed by Johnson & Johnson
NCT01585155 · Phase 3 · completed
No randomization, no blinding (masking: NONE), no control arm, single-group design with only 21 patients — this defaults to 'weak' per the design rules regardless of the favorable-looking remission percentages.
Next expected readout: December 2026 · NCT06839820 (registry estimate)
Reported efficacy
Percent of Patients Who Achieved CAI Remission (Weeks 2, 6, 8, 10, 14, 18, 22, 26, 30, and the last time point during the period from administration of the study drug to Week 30): Percent of Patients Who Achieved CAI Remission (Weeks 2, 6, 8, 10, 14, 18, 22, 26, 30, and the last time point during the period from administration of the study drug to Week 30): TA-650 — Weeks 2: 60%; Weeks 6: 80%; Weeks 8: 80%; Weeks 10: 77.8%; Weeks 14: 87.5%; Weeks 18: 87.5%; Weeks 22: 64.3%; Weeks 26: 85.7%; Weeks 30: 64.3%; The last time point: 42.9%
Result source: NCT01585155
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab | infliximab |
|---|---|---|
| Clinical remission (induction) | 10% vs 11.5%−1.5 vs placeboNCT008530996 other results
| —Trial running · NCT06614387 |
| Clinical remission (maintenance) | 20% vs 7.3%+12.7 vs placeboNCT0085309914 other results
| —Trial running · NCT06614387 |
| Clinical response (induction) | 50% vs 35.4%+14.6 vs placeboNCT008530994 other results
| —Trial running · NCT06614387 |
| Endoscopic improvement (induction) | 44.4% vs 30.2%+14.2 vs placeboNCT008530992 other results
| —Trial running · NCT06614387 |
| Corticosteroid-free remission (maintenance) | 13.3% vs 5.7%+7.6 vs placeboNCT004086295 other results
| —Trial running · NCT06614387 |
Clinical remission (induction)
- adalimumab
- 10% vs 11.5%−1.5 vs placeboNCT00853099
6 other results
- 13.8% vs 11.5% NCT00853099
- 10% vs 9.2% NCT00385736
- 18.5% vs 9.2% NCT00385736
- 16.5% vs 9.3% NCT00408629
- 10% vs 11.5% NCT00853099
- 13.8% vs 11.5% NCT00853099
- infliximab
- —Trial running · NCT06614387
Clinical remission (maintenance)
- adalimumab
- 20% vs 7.3%+12.7 vs placeboNCT00853099
14 other results
- 26.4% vs 7.3% NCT00853099
- 17.3% vs 8.5% NCT00408629
- 29% vs 33.3% NCT02065557
- 45.2% vs 33.3% NCT02065557
- 27.3% vs 33.3% NCT02065557
- 42.9% vs 33.3% NCT02065557
- 20% vs 7.3% NCT00853099
- 17.8% vs 8.3% NCT00853099
- 26.4% vs 7.3% NCT00853099
- 17.2% vs 8.3% NCT00853099
- 42.9% vs 37.5% NCT02065557
- 45.5% vs 37.5% NCT02065557
- 42.9% vs 37.5% NCT02065557
- 44% vs 37.5% NCT02065557
- infliximab
- —Trial running · NCT06614387
Clinical response (induction)
- adalimumab
- 50% vs 35.4%+14.6 vs placeboNCT00853099
4 other results
- 42.5% vs 35.4% NCT00853099
- 54.6% vs 44.6% NCT00385736
- 51.5% vs 44.6% NCT00385736
- 50.4% vs 34.6% NCT00408629
- infliximab
- —Trial running · NCT06614387
Endoscopic improvement (induction)
- adalimumab
- 44.4% vs 30.2%+14.2 vs placeboNCT00853099
2 other results
- 39.1% vs 30.2% NCT00853099
- 41.1% vs 31.7% NCT00408629
- infliximab
- —Trial running · NCT06614387
Corticosteroid-free remission (maintenance)
- adalimumab
- 13.3% vs 5.7%+7.6 vs placeboNCT00408629
5 other results
- 13.3% vs 5.7% NCT00408629
- 30.8% vs 40% NCT02065557
- 31.3% vs 40% NCT02065557
- 26.7% vs 40% NCT02065557
- 35.3% vs 40% NCT02065557
- infliximab
- —Trial running · NCT06614387
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. adalimumab: 5 of 5 rows · infliximab: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | adalimumab | infliximab |
|---|---|---|
| PUCAI Remission responder rate · % of participants No placebo or comparator arm | 40.7% (n=59) @ 288wk*a,b NCT02632175 · Phase 3 · monotherapy · converted to % from 24 Participants as posted | 18.2% (n=22) @ 54wk*5 mg/kg every 12 weeksc,a,b NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 · converted to % from 4 Participants as posted show 1 more dose38.1% (n=21) @ 54wk*5 mg/kg every 8 weeks NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 · converted to % from 8 Participants as posted |
| Dropout rate | 6.9%160/80/40d NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 18 more results9.2%80/40 NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 37.6%160/80/40 NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3 —Adalimumab Group - Double-Blind Pe NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 52.5% NCT02632175 · Phase 3 · monotherapy —high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —open-label high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —standard dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —standard dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 10.3%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 12.4%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study): TDM Regi NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 56.4%40 mg EOW/EW NCT00573794 · Phase 3 · monotherapy 34.1%160 mg/80 mg NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 33.3%80 mg/40 mg NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 23.8% NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 | 23.8%d NCT01585155 · Phase 3 · monotherapy show 3 more results47.8%5 mg/kg every 12 weeks NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 18.2%5 mg/kg every 8 weeks NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 50% NCT00791557 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | 3.1%160/80/40d NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 18 more results4.6%80/40 NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 5%160/80/40 NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3 —Adalimumab Group - Double-Blind Pe NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 — NCT02632175 · Phase 3 · monotherapy —high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —open-label high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —standard dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —standard dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 3.3%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 3.4%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study): TDM Regi NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 13.8%40 mg EOW/EW NCT00573794 · Phase 3 · monotherapy 14.3%160 mg/80 mg NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 10.3%80 mg/40 mg NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 5.6% NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 | 4.8%d NCT01585155 · Phase 3 · monotherapy show 3 more results26.1%5 mg/kg every 12 weeks NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 13.6%5 mg/kg every 8 weeks NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 50% NCT00791557 · Phase na · registry result, not featured evidence |
| Serious AEs | 4%160/80/40d NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 18 more results3.8%80/40 NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 —160/80/40 NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3 12.1%Adalimumab Group - Double-Blind Pe NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 27.1% NCT02632175 · Phase 3 · monotherapy 7.8%high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 5.6%open-label high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 15.6%standard dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 13.9%high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 15.2%standard dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 3.8%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 5%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 12.6%Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 12.8%Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 9.9%Maintenance (Main Study): TDM Regi NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 26.7%40 mg EOW/EW NCT00573794 · Phase 3 · monotherapy 11.1%160 mg/80 mg NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 16.1%80 mg/40 mg NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 14.5% NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 | 14.3%d NCT01585155 · Phase 3 · monotherapy show 3 more results21.7%5 mg/kg every 12 weeks NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 18.2%5 mg/kg every 8 weeks NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 0% NCT00791557 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | 160/80/40d colitis ulcerative 4% (placebo 3.6%) fatigue 4% (placebo 2.2%) headache 3.1% (placebo 7.2%) NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 17 more results80/40 headache 6.9% (placebo 7.2%) colitis ulcerative 5.4% (placebo 3.6%) nasopharyngitis 4.6% (placebo 1.8%) NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 nasopharyngitis 17.5% (placebo 10.4%) colitis ulcerative 16.3% (placebo 22.3%) headache 8.6% (placebo 14.2%) NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 colitis ulcerative 33.9% upper respiratory tract infection 27.1% nasopharyngitis 22% NCT02632175 · Phase 3 · monotherapy high dose headache 9.8% (placebo 16.7%) anaemia 5.9% (placebo 8.3%) nausea 5.9% (placebo 0%) NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 open-label high dose headache 22.2% (placebo 16.7%) abdominal pain 11.1% (placebo 8.3%) oropharyngeal pain 11.1% (placebo 0%) NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 standard dose headache 12.5% (placebo 16.7%) colitis ulcerative 6.3% (placebo 16.7%) nasopharyngitis 6.3% (placebo 8.3%) NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 high dose colitis ulcerative 11.1% (placebo 16.7%) nasopharyngitis 11.1% (placebo 8.3%) upper respiratory tract infection 11.1% (placebo 16.7%) NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 standard dose headache 18.2% (placebo 16.7%) c-reactive protein increased 9.1% (placebo 0%) colitis ulcerative 9.1% (placebo 16.7%) NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 headache 8.4% nasopharyngitis 5.1% arthralgia 3.1% NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 headache 6.1% colitis ulcerative 5.3% nasopharyngitis 4.2% NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 colitis ulcerative 13.4% nasopharyngitis 13.1% arthralgia 6.6% NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 colitis ulcerative 17.4% nasopharyngitis 13.6% arthralgia 6.7% NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 colitis ulcerative 15.2% nasopharyngitis 7.3% upper respiratory tract infection 6% NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 40 mg EOW/EW colitis ulcerative 30.4% viral upper respiratory tract infection 19.4% arthralgia 10.5% NCT00573794 · Phase 3 · monotherapy 160 mg/80 mg nasopharyngitis 33.3% (placebo 21.9%) iron deficiency anaemia 8.9% (placebo 7.3%) headache 7.8% (placebo 6.3%) NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 80 mg/40 mg nasopharyngitis 21.8% (placebo 21.9%) injection site reaction 8% (placebo 2.1%) dental caries 6.9% (placebo 5.2%) NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 colitis ulcerative 13.2% headache 13% nasopharyngitis 8% NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 | d double stranded dna antibody positive 57.1% nasopharyngitis 33.3% acne 9.5% NCT01585155 · Phase 3 · monotherapy show 3 more results5 mg/kg every 12 weeks colitis ulcerative 65.2% upper respiratory tract infection 26.1% pain 17.4% NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 5 mg/kg every 8 weeks colitis ulcerative 31.8% upper respiratory tract infection 31.8% fever 27.3% NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 bone marrow suppression 50% infection 50% infusion reaction 50% NCT00791557 · Phase na · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bAssessment timepoints differ: 288 weeks versus 54 weeks.
- cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- dPopulation comparability has not been reviewed for 2 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
adalimumab
show 6 more results
show 4 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 4 more results
show 14 more results
show 8 more results
show 2 more results
+ 50 further endpoints in the CSV export.
infliximab
+ 30 further endpoints in the CSV export.
Psoriasis
Shared mechanism: TNF-alpha · full Psoriasis pipeline
adalimumab · Humira
Marketed by AbbVie and partners
NCT00195676 · Phase 3 · completed
Eligibility for this study required prior participation in an earlier adalimumab psoriasis trial, making this an open-label continuation rather than a fresh, independently controlled study. Within the retreatment group, 76.5% of patients regained clear or minimal skin at 16 weeks, but with no placebo or comparison arm in this phase, that rate cannot be attributed to the drug with the same confidence as a controlled trial.
Next expected readout: April 2028 · NCT07529925 (registry estimate)
Reported efficacy
Percentage of Participants With a Physician's Global Assessment of Clear or Minimal at Week 16 of Period R: PGA 0/1 at 16 weeks after adalimumab retreatment: 89% in patients without relapse vs 69% in patients who relapsed; median time to relapse 141 days (178/285 stable-control patients relapsed) (not_applicable)
Result source: NCT00195676
infliximab · Remicade
Marketed by Johnson & Johnson
NCT00106847 · Phase 3 · completed
This randomized, double-blind trial enrolled 683 patients and measured the proportion achieving at least 75% skin clearance (PASI 75), a standard psoriasis efficacy measure, at week 10. Infliximab produced clearance rates of 70-75% depending on dose, compared with 2% on placebo, a highly statistically significant difference.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: June 2030 · NCT07352566 (registry estimate)
Reported efficacy
Percentage of Participants Who Achieved a Greater Than Equal to 75 Percent Response in Psoriasis Area and Severity Index (PASI) (Week 10): PASI 75 response at week 10: 81.0% infliximab (5 mg/kg) vs 2.2% placebo (P < 0.001) (met)
Result source: NCT01177800
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab | infliximab |
|---|---|---|
| PASI 75 | 77.8% vs 11.5%+66.3 vs placeboNCT016460737 other results
| 81% vs 2.2%+78.8 vs placeboNCT01177800 |
| PASI 90 | 61.8% vs 54.2%vs EU RPPNCT025813453 other results
| —Not posted · NCT00106847 |
| PASI 100 | 18.4% vs 2.7%vs MethotrexateNCT012516142 other results
| —Not posted · NCT00106847 |
| sPGA 0/1 | 60.5% vs 40.5%vs MethotrexateNCT0125161411 other results
| 88.1% vs 6.7%+81.4 vs placeboNCT011778001 other result
|
| DLQI, change | -4.8 vs -4.2−0.6 vs placeboNCT007357873 other results
| -8 vs -1.5−6.5 vs placeboNCT01177800 |
PASI 75
- adalimumab
- 77.8% vs 11.5%+66.3 vs placeboNCT01646073
7 other results
- 80.1% vs 79% NCT02581345
- 57.9% vs 32.4% NCT01251614
- 43.6% vs 32.4% NCT01251614
- 45.3% vs 2.3% NCT01646073
- 9.8% vs 0% NCT01646073
- 30.6% vs 8.7% NCT00735787
- 67% vs 27% NCT00932113
- infliximab
- 81% vs 2.2%+78.8 vs placeboNCT01177800
PASI 90
- adalimumab
- 61.8% vs 54.2%vs EU RPPNCT02581345
3 other results
- 28.9% vs 21.6% NCT01251614
- 30.8% vs 21.6% NCT01251614
- 20.4% vs 0% NCT00735787
- infliximab
- —Not posted · NCT00106847
PASI 100
- adalimumab
- 18.4% vs 2.7%vs MethotrexateNCT01251614
2 other results
- 10.3% vs 2.7% NCT01251614
- 14.3% vs 0% NCT00735787
- infliximab
- —Not posted · NCT00106847
sPGA 0/1
- adalimumab
- 60.5% vs 40.5%vs MethotrexateNCT01251614
11 other results
- 41% vs 40.5% NCT01251614
- 80.5% vs 14.9% NCT01646073
- 57.4% vs 4.6% NCT01646073
- 20.1% vs 0% NCT01646073
- 68.9% vs 66.1% NCT02581345
- 30.6% vs 4.3% NCT00735787
- 28.6% vs 13% NCT00735787
- 24.5% vs 8.7% NCT00735787
- 20.4% vs 4.3% NCT00735787
- 8.2% vs 4.3% NCT00735787
- 73% vs 27% NCT00932113
- infliximab
- 88.1% vs 6.7%+81.4 vs placeboNCT01177800
1 other result
- 0.8% vs 0.4% NCT00251641
DLQI, change
- adalimumab
- -4.8 vs -4.2−0.6 vs placeboNCT00735787
3 other results
- -7.9 vs -3.7 NCT01553058
- -4.1 vs -3.1 NCT00735787
- -4.3 vs -3.4 NCT00735787
- infliximab
- -8 vs -1.5−6.5 vs placeboNCT01177800
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
10 other shared endpoints and safety
Coverage. adalimumab: 14 of 14 rows · infliximab: 14 of 14 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | adalimumab Rows use multiple source trials | infliximab Rows use multiple source trials |
|---|---|---|
| DLQI absolute value · score Induction | 2.4 vs 2.1 EU RPP score @ 16wka,b,c NCT02581345 · Phase 3 · registry result, not featured evidence | 4.5 vs 9.25 placebo score @ 14wka,b,c NCT00629772 · Phase 3 · registry result, not featured evidence |
| DLQI absolute change · score Maintenance | -8 vs -1.9 placebo score @ 26wkEOWa,b NCT02016482 · Phase 3 · registry result, not featured evidence | -10.3 vs -9.2 placebo score @ 26wka,b NCT01177800 · Phase 3 |
| DLQI percent change · % of baseline No placebo or comparator arm | -79.16% (n=49) @ 24wka,b NCT01644396 · Phase 4 · registry result, not featured evidence | -68% (n=31) @ 24wk*5 mg/kga,b NCT00686595 · Phase 4 · registry result, not featured evidence · converted to % from 68 Percent reduction as posted |
| DLQI absolute change · score No placebo or comparator arm | -8 score @ 52wka,b,d NCT02533375 · Phase 3 · registry result, not featured evidence | 12.7 score @ 12wk5 mg/kga,b,d NCT00686686 · Phase 3 · registry result, not featured evidence |
| PASI 100 responder rate · % of participants No placebo or comparator arm | 64% (n=50) @ 24wka,b NCT01644396 · Phase 4 · registry result, not featured evidence | 40% (n=35) @ 24wk5 mg/kga,b NCT00686595 · Phase 4 · registry result, not featured evidence |
| PASI 50 responder rate · % of participants No placebo or comparator arm | 96% (n=50) @ 24wka,b NCT01644396 · Phase 4 · registry result, not featured evidence 3 other source trials40% (n=10) @ 24wk* NCT02533375 · Phase 3 · registry result, not featured evidence · converted to % from 4 Participants as posted 89.9% (n=89) @ 24wk*40 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 80 Participants as posted 94.8% (n=58) @ 24wk*80 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 55 Participants as posted | 89% (n=35) @ 24wk5 mg/kga,b NCT00686595 · Phase 4 · registry result, not featured evidence |
| PASI 75 responder rate · % of participants No placebo or comparator arm | 82% (n=50) @ 24wka,b NCT01644396 · Phase 4 · registry result, not featured evidence 4 other source trials40% (n=10) @ 24wk* NCT02533375 · Phase 3 · registry result, not featured evidence · converted to % from 4 Participants as posted 87.7% (n=333) @ 24wkEow NCT01646073 · Phase 3 · registry result, not featured evidence 77.5% (n=89) @ 24wk*40 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 69 Participants as posted 86.2% (n=58) @ 24wk*80 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 50 Participants as posted | 74% (n=35) @ 24wk5 mg/kga,b NCT00686595 · Phase 4 · registry result, not featured evidence |
| PASI 90 responder rate · % of participants No placebo or comparator arm | 76% (n=50) @ 24wka,b NCT01644396 · Phase 4 · registry result, not featured evidence 3 other source trials10% (n=10) @ 24wk* NCT02533375 · Phase 3 · registry result, not featured evidence · converted to % from 1 Participants as posted 56.2% (n=89) @ 24wk*40 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 50 Participants as posted 67.2% (n=58) @ 24wk*80 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 39 Participants as posted | 54% (n=35) @ 24wk5 mg/kga,b NCT00686595 · Phase 4 · registry result, not featured evidence |
| sPGA 0/1 responder rate · % of participants Maintenance | 24.5% (n=49) vs 8.7% (n=23) placebo @ 28wk*e,a,b,f NCT00735787 · Phase 4 · registry result, not featured evidence · converted to % from 12 subjects as posted | 0.73% (n=653) vs 0.28% (n=215) Methotrexate @ 26wke,a,b,f NCT00251641 · Phase 3 · registry result, not featured evidence |
| sPGA 0/1 responder rate · % of participants No placebo or comparator arm | 46.3% (n=1256) @ 120wka,b,g NCT00195676 · Phase 3 | 65.4% (n=211) @ 10wk*a,b,g NCT00527072 · Phase 3 · registry result, not featured evidence · converted to % from 138 participants as posted |
| Dropout rate | 41.3%h NCT00195676 · Phase 3 show 35 more results6.7% NCT00932113 · Phase 4 · registry result, not featured evidence 3% NCT01553058 · Phase 4 · registry result, not featured evidence 0% NCT01644396 · Phase 4 · registry result, not featured evidence 4.7% NCT01265823 · Phase 4 · registry result, not featured evidence 16.3% NCT00735787 · Phase 4 · registry result, not featured evidence 9.4% NCT05637515 · Phase 3 · registry result, not featured evidence 50% NCT02533375 · Phase 3 · registry result, not featured evidence 5.2%Part 1 and Part 2: M923 NCT02581345 · Phase 3 · registry result, not featured evidence —Part 1: M923 NCT02581345 · Phase 3 · registry result, not featured evidence —Part 2: M923 NCT02581345 · Phase 3 · registry result, not featured evidence 13.8%EOW NCT02016482 · Phase 3 · registry result, not featured evidence —EOW NCT02016482 · Phase 3 · registry result, not featured evidence —EOW NCT02016482 · Phase 3 · registry result, not featured evidence 21.1%0.8 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence —0.8 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence —0.8 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence 33.3%0.4 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence —0.4 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence —0.4 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence 1.5%Eow NCT01646073 · Phase 3 · registry result, not featured evidence —Eow NCT01646073 · Phase 3 · registry result, not featured evidence 11%Sub-optimal Response to Etanercept NCT00566722 · Phase 3 · registry result, not featured evidence 4.9%Sub-optimal Response to MTX NCT00566722 · Phase 3 · registry result, not featured evidence 17.2%Sub-optimal Response to Narrow-ban NCT00566722 · Phase 3 · registry result, not featured evidence —40 mg every week NCT00927069 · Phase 3 · registry result, not featured evidence —40 mg every week NCT00927069 · Phase 3 · registry result, not featured evidence 2%Group A NCT00927069 · Phase 3 · registry result, not featured evidence 2.9%Group B NCT00927069 · Phase 3 · registry result, not featured evidence 7.7%Adalimumab + Calcipotriol/Betameth NCT00574249 · Phase 3 · registry result, not featured evidence · combination 7.1%Adalimumab + Placebo NCT00574249 · Phase 3 · registry result, not featured evidence 11.8%40 mg Eow NCT00513370 · Phase 3 · registry result, not featured evidence 22.4%80 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence 24.7%40 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence 0% NCT01872546 · Phase 2 · registry result, not featured evidence 11.1% NCT01320293 · Phase na · registry result, not featured evidence | 11.9%h NCT01177800 · Phase 3 show 17 more results18.4%5 mg/kg NCT00686595 · Phase 4 · registry result, not featured evidence —TA-650(Dose Escalation Period)Over NCT01680159 · Phase 3 · registry result, not featured evidence —TA-650(Dose Escalation Period)Plaq NCT01680159 · Phase 3 · registry result, not featured evidence —TA-650(Dose Escalation Period)Psor NCT01680159 · Phase 3 · registry result, not featured evidence —TA-650(Dose Escalation Period)Psor NCT01680159 · Phase 3 · registry result, not featured evidence —TA-650(Dose Escalation Period)Pust NCT01680159 · Phase 3 · registry result, not featured evidence —TA-650(Entire Evaluation Period)Pl NCT01680159 · Phase 3 · registry result, not featured evidence —TA-650(Entire Evaluation Period)Ps NCT01680159 · Phase 3 · registry result, not featured evidence —TA-650(Normal Dose Period)Overall NCT01680159 · Phase 3 · registry result, not featured evidence —TA-650(Normal Dose Period)Plaque P NCT01680159 · Phase 3 · registry result, not featured evidence —TA-650(Normal Dose Period)Psoriati NCT01680159 · Phase 3 · registry result, not featured evidence 16.7% NCT00527072 · Phase 3 · registry result, not featured evidence 0% NCT00629772 · Phase 3 · registry result, not featured evidence 18.9%5 mg/kg NCT00687401 · Phase 3 · registry result, not featured evidence 26.1%5 mg/kg NCT00686686 · Phase 3 · registry result, not featured evidence 17.2% NCT00251641 · Phase 3 · registry result, not featured evidence 13.6%5 mg/kg NCT00687362 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 5.6%h NCT00195676 · Phase 3 show 35 more results— NCT00932113 · Phase 4 · registry result, not featured evidence — NCT01553058 · Phase 4 · registry result, not featured evidence — NCT01644396 · Phase 4 · registry result, not featured evidence — NCT01265823 · Phase 4 · registry result, not featured evidence — NCT00735787 · Phase 4 · registry result, not featured evidence — NCT05637515 · Phase 3 · registry result, not featured evidence 20% NCT02533375 · Phase 3 · registry result, not featured evidence 1%Part 1 and Part 2: M923 NCT02581345 · Phase 3 · registry result, not featured evidence —Part 1: M923 NCT02581345 · Phase 3 · registry result, not featured evidence —Part 2: M923 NCT02581345 · Phase 3 · registry result, not featured evidence 4.6%EOW NCT02016482 · Phase 3 · registry result, not featured evidence —EOW NCT02016482 · Phase 3 · registry result, not featured evidence —EOW NCT02016482 · Phase 3 · registry result, not featured evidence 2.6%0.8 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence —0.8 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence —0.8 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence 0%0.4 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence —0.4 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence —0.4 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence 0.6%Eow NCT01646073 · Phase 3 · registry result, not featured evidence —Eow NCT01646073 · Phase 3 · registry result, not featured evidence 0%Sub-optimal Response to Etanercept NCT00566722 · Phase 3 · registry result, not featured evidence 0%Sub-optimal Response to MTX NCT00566722 · Phase 3 · registry result, not featured evidence 6.9%Sub-optimal Response to Narrow-ban NCT00566722 · Phase 3 · registry result, not featured evidence —40 mg every week NCT00927069 · Phase 3 · registry result, not featured evidence —40 mg every week NCT00927069 · Phase 3 · registry result, not featured evidence —Group A NCT00927069 · Phase 3 · registry result, not featured evidence —Group B NCT00927069 · Phase 3 · registry result, not featured evidence 4.9%Adalimumab + Calcipotriol/Betameth NCT00574249 · Phase 3 · registry result, not featured evidence · combination 1.6%Adalimumab + Placebo NCT00574249 · Phase 3 · registry result, not featured evidence —40 mg Eow NCT00513370 · Phase 3 · registry result, not featured evidence —80 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence —40 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence — NCT01872546 · Phase 2 · registry result, not featured evidence 5.6% NCT01320293 · Phase na · registry result, not featured evidence | 10.7%h NCT01177800 · Phase 3 show 17 more results7.9%5 mg/kg NCT00686595 · Phase 4 · registry result, not featured evidence —TA-650(Dose Escalation Period)Over NCT01680159 · Phase 3 · registry result, not featured evidence —TA-650(Dose Escalation Period)Plaq NCT01680159 · Phase 3 · registry result, not featured evidence —TA-650(Dose Escalation Period)Psor NCT01680159 · Phase 3 · registry result, not featured evidence —TA-650(Dose Escalation Period)Psor NCT01680159 · Phase 3 · registry result, not featured evidence —TA-650(Dose Escalation Period)Pust NCT01680159 · Phase 3 · registry result, not featured evidence —TA-650(Entire Evaluation Period)Pl NCT01680159 · Phase 3 · registry result, not featured evidence —TA-650(Entire Evaluation Period)Ps NCT01680159 · Phase 3 · registry result, not featured evidence —TA-650(Normal Dose Period)Overall NCT01680159 · Phase 3 · registry result, not featured evidence —TA-650(Normal Dose Period)Plaque P NCT01680159 · Phase 3 · registry result, not featured evidence —TA-650(Normal Dose Period)Psoriati NCT01680159 · Phase 3 · registry result, not featured evidence 6% NCT00527072 · Phase 3 · registry result, not featured evidence — NCT00629772 · Phase 3 · registry result, not featured evidence 3.8%5 mg/kg NCT00687401 · Phase 3 · registry result, not featured evidence 8.7%5 mg/kg NCT00686686 · Phase 3 · registry result, not featured evidence 12.3% NCT00251641 · Phase 3 · registry result, not featured evidence —5 mg/kg NCT00687362 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 12.9%h NCT00195676 · Phase 3 show 35 more results0% NCT00932113 · Phase 4 · registry result, not featured evidence 6.1% NCT01553058 · Phase 4 · registry result, not featured evidence 0% NCT01644396 · Phase 4 · registry result, not featured evidence 0.7% NCT01265823 · Phase 4 · registry result, not featured evidence 4.1% NCT00735787 · Phase 4 · registry result, not featured evidence 1.7% NCT05637515 · Phase 3 · registry result, not featured evidence 30% NCT02533375 · Phase 3 · registry result, not featured evidence —Part 1 and Part 2: M923 NCT02581345 · Phase 3 · registry result, not featured evidence 1.4%Part 1: M923 NCT02581345 · Phase 3 · registry result, not featured evidence 3.7%Part 2: M923 NCT02581345 · Phase 3 · registry result, not featured evidence —EOW NCT02016482 · Phase 3 · registry result, not featured evidence 7.3%EOW NCT02016482 · Phase 3 · registry result, not featured evidence 3.2%EOW NCT02016482 · Phase 3 · registry result, not featured evidence 0%0.8 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence 0%0.8 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence 5.7%0.8 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence 7.7%0.4 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence 0%0.4 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence 0%0.4 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence —Eow NCT01646073 · Phase 3 · registry result, not featured evidence 1.2%Eow NCT01646073 · Phase 3 · registry result, not featured evidence 4.9%Sub-optimal Response to Etanercept NCT00566722 · Phase 3 · registry result, not featured evidence 0%Sub-optimal Response to MTX NCT00566722 · Phase 3 · registry result, not featured evidence 3.4%Sub-optimal Response to Narrow-ban NCT00566722 · Phase 3 · registry result, not featured evidence —40 mg every week NCT00927069 · Phase 3 · registry result, not featured evidence —40 mg every week NCT00927069 · Phase 3 · registry result, not featured evidence 0%Group A NCT00927069 · Phase 3 · registry result, not featured evidence 0%Group B NCT00927069 · Phase 3 · registry result, not featured evidence 4.4%Adalimumab + Calcipotriol/Betameth NCT00574249 · Phase 3 · registry result, not featured evidence · combination 4.1%Adalimumab + Placebo NCT00574249 · Phase 3 · registry result, not featured evidence —40 mg Eow NCT00513370 · Phase 3 · registry result, not featured evidence 19%80 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence 21.3%40 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence 0% NCT01872546 · Phase 2 · registry result, not featured evidence 5.6% NCT01320293 · Phase na · registry result, not featured evidence | 4.8%h NCT01177800 · Phase 3 show 17 more results18.4%5 mg/kg NCT00686595 · Phase 4 · registry result, not featured evidence 9.8%TA-650(Dose Escalation Period)Over NCT01680159 · Phase 3 · registry result, not featured evidence 12.9%TA-650(Dose Escalation Period)Plaq NCT01680159 · Phase 3 · registry result, not featured evidence 0%TA-650(Dose Escalation Period)Psor NCT01680159 · Phase 3 · registry result, not featured evidence 0%TA-650(Dose Escalation Period)Psor NCT01680159 · Phase 3 · registry result, not featured evidence 14.3%TA-650(Dose Escalation Period)Pust NCT01680159 · Phase 3 · registry result, not featured evidence 11.1%TA-650(Entire Evaluation Period)Pl NCT01680159 · Phase 3 · registry result, not featured evidence 0%TA-650(Entire Evaluation Period)Ps NCT01680159 · Phase 3 · registry result, not featured evidence 0%TA-650(Normal Dose Period)Overall NCT01680159 · Phase 3 · registry result, not featured evidence 0%TA-650(Normal Dose Period)Plaque P NCT01680159 · Phase 3 · registry result, not featured evidence 0%TA-650(Normal Dose Period)Psoriati NCT01680159 · Phase 3 · registry result, not featured evidence 3.7% NCT00527072 · Phase 3 · registry result, not featured evidence 16.7% NCT00629772 · Phase 3 · registry result, not featured evidence 1.3%5 mg/kg NCT00687401 · Phase 3 · registry result, not featured evidence 17.4%5 mg/kg NCT00686686 · Phase 3 · registry result, not featured evidence 6.8% NCT00251641 · Phase 3 · registry result, not featured evidence 0%5 mg/kg NCT00687362 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | show 29 more resultsupper respiratory tract infection 40% dizziness 13.3% flu-like symptoms 13.3% NCT00932113 · Phase 4 · registry result, not featured evidence upper respiratory infection 9.1% (placebo 12.9%) joint range of motion decrease 6.1% (placebo 0%) headache 3% (placebo 6.5%) NCT01553058 · Phase 4 · registry result, not featured evidence latent tuberculosis 8% rhinitis 6% alanine aminotransferase increased 2% NCT01644396 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 11.3% hyperglycemia 10.7% arthralgia 6.7% NCT01265823 · Phase 4 · registry result, not featured evidence nasopharyngitis 26.5% (placebo 13%) headache 14.3% (placebo 4.3%) cough 8.2% (placebo 4.3%) NCT00735787 · Phase 4 · registry result, not featured evidence headache 2.2% nasopharyngitis 2.2% upper respiratory tract infection 2.2% NCT05637515 · Phase 3 · registry result, not featured evidence nasopharyngitis 30% pruritus 30% hypoalbuminaemia 20% NCT02533375 · Phase 3 · registry result, not featured evidence injection site reaction 23.9% nasopharyngitis 6.7% headache 3.2% NCT02581345 · Phase 3 · registry result, not featured evidence nasopharyngitis 14.8% psoriasis 10.3% injection site reaction 10% NCT02581345 · Phase 3 · registry result, not featured evidence EOW upper respiratory tract infection 8.3% (placebo 8.3%) headache 5.5% (placebo 0%) nasopharyngitis 5.5% (placebo 9.3%) NCT02016482 · Phase 3 · registry result, not featured evidence EOW nasopharyngitis 12.8% (placebo 9.3%) upper respiratory tract infection 4.3% (placebo 8.3%) depression 3.2% (placebo 0.9%) NCT02016482 · Phase 3 · registry result, not featured evidence 0.8 mg/kg nasopharyngitis 21.1% headache 15.8% dry skin 7.9% NCT01251614 · Phase 3 · registry result, not featured evidence 0.8 mg/kg nasopharyngitis 18.5% back pain 11.1% headache 11.1% NCT01251614 · Phase 3 · registry result, not featured evidence 0.8 mg/kg nasopharyngitis 28.7% headache 25.3% upper respiratory tract infection 14.9% NCT01251614 · Phase 3 · registry result, not featured evidence 0.4 mg/kg nasopharyngitis 25.6% headache 17.9% cough 10.3% NCT01251614 · Phase 3 · registry result, not featured evidence 0.4 mg/kg cough 18.2% decreased appetite 9.1% gastroenteritis 9.1% NCT01251614 · Phase 3 · registry result, not featured evidence 0.4 mg/kg nasopharyngitis 23.1% agitation 7.7% cough 7.7% NCT01251614 · Phase 3 · registry result, not featured evidence Eow upper respiratory tract infection 10.1% (placebo 6.9%) oropharyngeal pain 4.1% (placebo 1.1%) nasopharyngitis 3.8% (placebo 5.7%) NCT01646073 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 6.1% cough 3.7% headache 3.7% NCT00566722 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 12.2% injection site erythema 7.3% nasopharyngitis 7.3% NCT00566722 · Phase 3 · registry result, not featured evidence fatigue 6.9% pharyngitis 6.9% abdominal pain 3.4% NCT00566722 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 18% back pain 8% common cold 8% NCT00927069 · Phase 3 · registry result, not featured evidence headache 11.4% common cold 5.7% upper respiratory tract infection 5.7% NCT00927069 · Phase 3 · registry result, not featured evidence nasopharyngitis 8.7% headache 5.2% psoriasis 5.2% NCT00574249 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 6.3% headache 6% pruritus 5.8% NCT00574249 · Phase 3 · registry result, not featured evidence 40 mg Eow nasopharyngitis 10.8% upper respiratory tract infection 10.8% headache 4.9% NCT00513370 · Phase 3 · registry result, not featured evidence 80 mg every other week nasopharyngitis 77.6% blood triglycerides increased 29.3% blood creatine phosphokinase increased 25.9% NCT00647400 · Phase 2/3 · registry result, not featured evidence 40 mg every other week nasopharyngitis 75.3% blood triglycerides increased 24.7% alanine aminotransferase increased 23.6% NCT00647400 · Phase 2/3 · registry result, not featured evidence upper respiratory tract infection 22.2% elbow strain 5.6% heartburn 5.6% NCT01320293 · Phase na · registry result, not featured evidence | h upper respiratory tract infection 14.3% (placebo 11.1%) antinuclear antibody positive 11.9% (placebo 6.7%) asthenia 11.9% (placebo 11.1%) NCT01177800 · Phase 3 show 17 more results5 mg/kg pruritus 10.5% rhinitis 7.9% blood triglycerides increased 5.3% NCT00686595 · Phase 4 · registry result, not featured evidence double stranded dna antibody positive 49% nasopharyngitis 27.5% headache 7.8% NCT01680159 · Phase 3 · registry result, not featured evidence double stranded dna antibody positive 58.1% nasopharyngitis 22.6% dyspnoea 9.7% NCT01680159 · Phase 3 · registry result, not featured evidence double stranded dna antibody positive 25% alanine aminotransferase increased 12.5% arthralgia 12.5% NCT01680159 · Phase 3 · registry result, not featured evidence nasopharyngitis 60% double stranded dna antibody positive 40% alanine aminotransferase increased 20% NCT01680159 · Phase 3 · registry result, not featured evidence double stranded dna antibody positive 42.9% nasopharyngitis 42.9% chapped lips 14.3% NCT01680159 · Phase 3 · registry result, not featured evidence double stranded dna antibody positive 69.4% nasopharyngitis 22.2% dyspnoea 8.3% NCT01680159 · Phase 3 · registry result, not featured evidence double stranded dna antibody positive 60% alanine aminotransferase increased 10% arthralgia 10% NCT01680159 · Phase 3 · registry result, not featured evidence double stranded dna antibody positive 34.8% nasopharyngitis 8.7% psoriasis 4.3% NCT01680159 · Phase 3 · registry result, not featured evidence double stranded dna antibody positive 33.3% nasopharyngitis 11.1% aspartate aminotransferase increased 2.8% NCT01680159 · Phase 3 · registry result, not featured evidence double stranded dna antibody positive 40% erythema 10% feeling hot 10% NCT01680159 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 9.8% arthralgia 8.8% headache 6.5% NCT00527072 · Phase 3 · registry result, not featured evidence common cold 25% (placebo 25%) fatigue 16.7% (placebo 8.3%) joint pain in hand 16.7% (placebo 0%) NCT00629772 · Phase 3 · registry result, not featured evidence 5 mg/kg hepatic enzyme increased 13% asthenia 8.7% folliculitis 8.7% NCT00686686 · Phase 3 · registry result, not featured evidence nasopharyngitis 18.3% infusion related reaction 10.8% headache 10.2% NCT00251641 · Phase 3 · registry result, not featured evidence 5 mg/kg pyrexia 18.2% cough 13.6% oropharyngeal pain 13.6% NCT00687362 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cAssessment timepoints differ: 16 weeks versus 14 weeks.
- dAssessment timepoints differ: 52 weeks versus 12 weeks.
- eTrial phases differ: Phase 4 versus Phase 3.
- fAssessment timepoints differ: 28 weeks versus 26 weeks.
- gAssessment timepoints differ: 120 weeks versus 10 weeks.
- hPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
adalimumab
show 11 more results
show 5 more results
show 15 more results
show 2 more results
show 1 more result
+ 170 further endpoints in the CSV export.
infliximab
show 1 more result
show 1 more result
show 1 more result
show 1 more result
Rheumatoid Arthritis
Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline
adalimumab · Humira
Marketed by AbbVie and partners
NCT00195702 · Phase 3 · completed
This was a large, randomized, double-blind, placebo-controlled trial. More patients on adalimumab responded on the ACR20 joint-response measure than on placebo (about 61-63% vs about 30%, p<0.001 for both doses), and adalimumab also significantly slowed radiographic joint damage and improved physical function compared with placebo (p<0.001 for both).
Next expected readout: December 2027 · NCT06440629 (registry estimate)
Reported efficacy
Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 24; Change From Baseline in Modified Total Sharp X-ray Score at Week 52 (Baseline and Week 52); Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 52 (Baseline and Week 52): Primary 1, ACR20 at week 24: 63% (40 mg every other week) and 61% (20 mg weekly) vs 30% placebo, all with methotrexate (P<=0.001 for each), met. Primary 2, change in modified total Sharp score at week 52: 0.1 and 0.8 vs 2.7 (P<=0.001 for each), met. Primary 3, change in HAQ disability index at week 52: -0.59 and -0.61 vs -0.25 (P<=0.001 for each), met. (met)
Result source: NCT00195702
infliximab · Remicade
Marketed by Johnson & Johnson
NCT00269867 · Phase 3 · completed
This randomised, double-blind, placebo-controlled trial in 428 patients with rheumatoid arthritis (ATTRACT) reported ACR20 responses of 50-58% across the infliximab plus methotrexate regimens against 20% on placebo plus methotrexate at week 30 (P<0.001 for each regimen), on a validated measure of disease activity.
Next expected readout: March 2028 · NCT03414502 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Rheumatoid Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab | infliximab |
|---|---|---|
| ACR20 | 63.3% vs 29.5%+33.8 vs placeboNCT0019570228 other results
| 56.6% vs 53%vs Remicade-USNCT0299080651 other results
|
| ACR50 | 41.2% vs 45.9%vs MethotrexateNCT0019566319 other results
| 34.4% vs 32.3%vs Remicade USNCT0299080650 other results
|
| ACR70 | 47.4% vs 22.7%+24.7 vs placeboNCT0087046716 other results
| 16.3% vs 14.5%vs Remicade USNCT0299080649 other results
|
| DAS28-CRP remission | 38.5% vs 42.9%vs Standard of CareNCT011624215 other results
| —Not posted · NCT01217086 |
| HAQ-DI, change | -0.6 vs -0.3−0.3 vs placeboNCT0019570222 other results
| -0.4 vs -0.4vs Remicade USNCT0299080624 other results
|
| Modified Sharp score, change | 0.1 vs 2.7−2.6 vs placeboNCT0019570215 other results
| —Not posted · NCT01217086 |
ACR20
- adalimumab
- 63.3% vs 29.5%+33.8 vs placeboNCT00195702
28 other results
- 50.3% vs 33.9% NCT00647270
- 57% vs 35% NCT00538902
- 47.3% vs 33.9% NCT00647270
- 51.2% vs 35% NCT00538902
- 60.8% vs 29.5% NCT00195702
- 58.9% vs 24% NCT00195702
- 54.7% vs 24% NCT00195702
- 75.4% vs 56.4% NCT00870467
- 53.3% vs 61.5% NCT00195663
- 68.7% vs 61.5% NCT00195663
- 54.4% vs 62.6% NCT00195663
- 72.8% vs 62.6% NCT00195663
- 50% vs 59.9% NCT00195663
- 69% vs 59.9% NCT00195663
- 49.3% vs 56% NCT00195663
- 69.4% vs 56% NCT00195663
- 69.2% vs 71.4% NCT01500278
- 84.8% vs 80.4% NCT00420927
- 66.4% vs 80.4% NCT00420927
- 64.5% vs 60.8% NCT01500278
- 68% vs 68% NCT01712178
- 62% vs 68% NCT01712178
- 64.1% vs 37.1% NCT01162421
- 69.2% vs 57.1% NCT01162421
- 66.7% vs 60% NCT01162421
- 56.4% vs 68.6% NCT01162421
- 51.3% vs 65.7% NCT01162421
- 46.2% vs 65.7% NCT01162421
- infliximab
- 56.6% vs 53%vs Remicade-USNCT02990806
51 other results
- 62.6% vs 56.5% NCT02990806
- 61.9% vs 56.5% NCT02990806
- 60.8% vs 55.6% NCT02990806
- 62.4% vs 55.6% NCT02990806
- 56.8% vs 54.5% NCT02990806
- 55.5% vs 48.8% NCT02990806
- 57.9% vs 48.8% NCT02990806
- 55.9% vs 56.3% NCT02990806
- 58.1% vs 50% NCT02990806
- 57.4% vs 50% NCT02990806
- 62.6% vs 61.7% NCT02990806
- 61.7% vs 55.6% NCT02990806
- 61.4% vs 55.6% NCT02990806
- 62.6% vs 62.3% NCT02990806
- 62.1% vs 56.9% NCT02990806
- 61.4% vs 56.9% NCT02990806
- 56.4% vs 51.1% NCT02990806
- 52% vs 47.6% NCT02990806
- 57.9% vs 47.6% NCT02990806
- 56.8% vs 52.2% NCT02990806
- 56.4% vs 48.8% NCT02990806
- 59.4% vs 48.8% NCT02990806
- 54.6% vs 53.6% NCT02990806
- 59.4% vs 53.6% NCT02990806
- 57.3% vs 54.4% NCT02990806
- 60.9% vs 54.4% NCT02990806
- 47.1% vs 54.3% NCT02990806
- 51.1% vs 48% NCT02990806
- 51.3% vs 48% NCT02990806
- 46.7% vs 54.3% NCT02990806
- 53.7% vs 50% NCT02990806
- 54.3% vs 50% NCT02990806
- 31.3% vs 32.5% NCT02990806
- 54.2% vs 50% NCT02990806
- 59.9% vs 50% NCT02990806
- 29.1% vs 31.8% NCT02990806
- 56.4% vs 50.8% NCT02990806
- 59.4% vs 50.8% NCT02990806
- 52.4% vs 47.2% NCT02990806
- 49.2% vs 47.2% NCT02990806
- 54.6% vs 47.2% NCT02990806
- 50.8% vs 47.2% NCT02990806
- 52.4% vs 46.4% NCT02990806
- 56.9% vs 46.4% NCT02990806
- 54.2% vs 48.8% NCT02990806
- 55.8% vs 48.8% NCT02990806
- 52% vs 46.4% NCT02990806
- 55.3% vs 46.4% NCT02990806
- 52.4% vs 47.2% NCT02990806
- 54.3% vs 47.2% NCT02990806
- 56.7% vs 32.3% NCT01313520
ACR50
- adalimumab
- 41.2% vs 45.9%vs MethotrexateNCT00195663
19 other results
- 61.6% vs 45.9% NCT00195663
- 64.3% vs 38.7% NCT00870467
- 35% vs 40.5% NCT00195663
- 58.6% vs 40.5% NCT00195663
- 41.6% vs 44.4% NCT00195663
- 60.1% vs 44.4% NCT00195663
- 36.9% vs 42.8% NCT00195663
- 59% vs 42.8% NCT00195663
- 78.1% vs 69.6% NCT00420927
- 46.3% vs 69.6% NCT00420927
- 48% vs 50% NCT01712178
- 36% vs 40% NCT01712178
- 43.6% vs 22.9% NCT01162421
- 38.5% vs 22.9% NCT01162421
- 48.7% vs 40% NCT01162421
- 64.7% vs 51.6% NCT03823391
- 43.6% vs 34.3% NCT01162421
- 38.5% vs 45.7% NCT01162421
- 33.3% vs 42.9% NCT01162421
- infliximab
- 34.4% vs 32.3%vs Remicade USNCT02990806
50 other results
- 31% vs 32.3% NCT02990806
- 33% vs 31.9% NCT02990806
- 30.5% vs 31.9% NCT02990806
- 27.8% vs 25.6% NCT02990806
- 30% vs 28.6% NCT02990806
- 29.4% vs 28.6% NCT02990806
- 27.8% vs 26.7% NCT02990806
- 29.1% vs 28.2% NCT02990806
- 28.4% vs 28.2% NCT02990806
- 32.2% vs 30.9% NCT02990806
- 35.2% vs 34.3% NCT02990806
- 39.1% vs 34.3% NCT02990806
- 31.7% vs 29.6% NCT02990806
- 35.2% vs 34.7% NCT02990806
- 39.1% vs 34.7% NCT02990806
- 24.7% vs 21.3% NCT02990806
- 31.3% vs 30.2% NCT02990806
- 34% vs 30.2% NCT02990806
- 23.3% vs 21.7% NCT02990806
- 32.2% vs 30.6% NCT02990806
- 32.5% vs 30.6% NCT02990806
- 33.5% vs 36.7% NCT02990806
- 40.6% vs 36.7% NCT02990806
- 33.5% vs 36.7% NCT02990806
- 37.1% vs 36.7% NCT02990806
- 16.3% vs 19.1% NCT02990806
- 30.8% vs 31.5% NCT02990806
- 30.5% vs 31.5% NCT02990806
- 14.5% vs 17.9% NCT02990806
- 29.5% vs 31.5% NCT02990806
- 29.4% vs 31.5% NCT02990806
- 8.4% vs 8.3% NCT02990806
- 37% vs 34.7% NCT02990806
- 35.5% vs 34.7% NCT02990806
- 6.6% vs 6.7% NCT02990806
- 34.8% vs 34.3% NCT02990806
- 34.5% vs 34.3% NCT02990806
- 36.6% vs 28.6% NCT02990806
- 32.5% vs 28.6% NCT02990806
- 36.1% vs 28.6% NCT02990806
- 29.4% vs 28.6% NCT02990806
- 32.6% vs 32.7% NCT02990806
- 34% vs 32.7% NCT02990806
- 32.6% vs 32.3% NCT02990806
- 33.5% vs 32.3% NCT02990806
- 30.8% vs 32.7% NCT02990806
- 28.4% vs 32.7% NCT02990806
- 29.1% vs 32.7% NCT02990806
- 27.9% vs 32.7% NCT02990806
- 20% vs 0% NCT01313520
ACR70
- adalimumab
- 47.4% vs 22.7%+24.7 vs placeboNCT00870467
16 other results
- 19.7% vs 22.2% NCT00195663
- 42.5% vs 22.2% NCT00195663
- 25.9% vs 27.2% NCT00195663
- 45.5% vs 27.2% NCT00195663
- 28.8% vs 29.2% NCT00195663
- 47.4% vs 29.2% NCT00195663
- 28.1% vs 28.4% NCT00195663
- 46.6% vs 28.4% NCT00195663
- 69.5% vs 57.1% NCT00420927
- 30.1% vs 57.1% NCT00420927
- 28.2% vs 8.6% NCT01162421
- 15.4% vs 2.9% NCT01162421
- 25.6% vs 22.9% NCT01162421
- 30.8% vs 14.3% NCT01162421
- 30.8% vs 20% NCT01162421
- 23.1% vs 40% NCT01162421
- infliximab
- 16.3% vs 14.5%vs Remicade USNCT02990806
49 other results
- 13.2% vs 14.5% NCT02990806
- 15.4% vs 15.3% NCT02990806
- 12.7% vs 15.3% NCT02990806
- 10.6% vs 12.1% NCT02990806
- 16.3% vs 15.3% NCT02990806
- 13.2% vs 15.3% NCT02990806
- 11% vs 11.2% NCT02990806
- 15.4% vs 14.1% NCT02990806
- 11.7% vs 14.1% NCT02990806
- 15% vs 11.7% NCT02990806
- 18.1% vs 18.1% NCT02990806
- 20.8% vs 18.1% NCT02990806
- 14.5% vs 11% NCT02990806
- 16.7% vs 16.9% NCT02990806
- 19.3% vs 16.9% NCT02990806
- 11% vs 7.8% NCT02990806
- 17.6% vs 15.7% NCT02990806
- 14.7% vs 15.7% NCT02990806
- 9.7% vs 7.4% NCT02990806
- 16.3% vs 16.1% NCT02990806
- 14.2% vs 16.1% NCT02990806
- 17.2% vs 18.5% NCT02990806
- 18.3% vs 18.5% NCT02990806
- 14.5% vs 17.3% NCT02990806
- 15.7% vs 17.3% NCT02990806
- 6.6% vs 7.2% NCT02990806
- 15% vs 18.5% NCT02990806
- 14.7% vs 18.5% NCT02990806
- 5.7% vs 6.1% NCT02990806
- 15.4% vs 16.9% NCT02990806
- 13.2% vs 16.9% NCT02990806
- 0.9% vs 1.3% NCT02990806
- 22% vs 23% NCT02990806
- 18.3% vs 23% NCT02990806
- 0.9% vs 1.1% NCT02990806
- 20.7% vs 22.6% NCT02990806
- 15.7% vs 22.6% NCT02990806
- 18.1% vs 14.9% NCT02990806
- 15.7% vs 14.9% NCT02990806
- 17.2% vs 13.3% NCT02990806
- 13.7% vs 13.3% NCT02990806
- 18.9% vs 19.8% NCT02990806
- 16.2% vs 19.8% NCT02990806
- 17.2% vs 18.1% NCT02990806
- 14.7% vs 18.1% NCT02990806
- 17.2% vs 18.5% NCT02990806
- 13.2% vs 18.5% NCT02990806
- 16.3% vs 18.1% NCT02990806
- 15.2% vs 18.1% NCT02990806
DAS28-CRP remission
- adalimumab
- 38.5% vs 42.9%vs Standard of CareNCT01162421
5 other results
- 30.8% vs 34.3% NCT01162421
- 35.9% vs 22.9% NCT01162421
- 28.2% vs 31.4% NCT01162421
- 35.9% vs 11.4% NCT01162421
- 17.9% vs 8.6% NCT01162421
- infliximab
- —Not posted · NCT01217086
HAQ-DI, change
- adalimumab
- -0.6 vs -0.3−0.3 vs placeboNCT00195702
22 other results
- -0.6 vs -0.3 NCT00195702
- -0.6 vs -0.2 NCT00195702
- -0.4 vs -0.1 NCT00647270
- -0.4 vs -0.1 NCT00647270
- -0.3 vs 0 NCT00647270
- -0.2 vs 0 NCT00647270
- -0.5 vs -0.3 NCT00538902
- -0.4 vs -0.1 NCT00647270
- -0.4 vs -0.1 NCT00647270
- -0.2 vs 0 NCT00647270
- -0.2 vs 0 NCT00647270
- -0.4 vs -0.3 NCT00538902
- -0.6 vs -0.2 NCT00195702
- -0.8 vs -0.8 NCT00195663
- -1.1 vs -0.8 NCT00195663
- -0.6 vs -0.7 NCT01500278
- -0.5 vs -0.3 NCT01162421
- -0.4 vs -0.4 NCT01162421
- -0.5 vs -0.5 NCT01162421
- -0.5 vs -0.6 NCT01162421
- -0.6 vs -0.6 NCT01162421
- -0.5 vs -0.6 NCT01162421
- infliximab
- -0.4 vs -0.4vs Remicade USNCT02990806
24 other results
- -0.4 vs -0.4 NCT02990806
- -0.3 vs -0.4 NCT02990806
- -0.4 vs -0.5 NCT02990806
- -0.4 vs -0.5 NCT02990806
- -0.4 vs -0.4 NCT02990806
- -0.5 vs -0.5 NCT02990806
- -0.4 vs -0.5 NCT02990806
- -0.3 vs -0.3 NCT02990806
- -0.4 vs -0.5 NCT02990806
- -0.4 vs -0.5 NCT02990806
- -0.5 vs -0.5 NCT02990806
- -0.5 vs -0.5 NCT02990806
- -0.3 vs -0.4 NCT02990806
- -0.5 vs -0.5 NCT02990806
- -0.4 vs -0.5 NCT02990806
- -0.2 vs -0.3 NCT02990806
- -0.5 vs -0.6 NCT02990806
- -0.5 vs -0.6 NCT02990806
- -0.5 vs -0.5 NCT02990806
- -0.4 vs -0.5 NCT02990806
- -0.5 vs -0.5 NCT02990806
- -0.4 vs -0.5 NCT02990806
- -0.5 vs -0.5 NCT02990806
- -0.4 vs -0.5 NCT02990806
Modified Sharp score, change
- adalimumab
- 0.1 vs 2.7−2.6 vs placeboNCT00195702
15 other results
- 0.8 vs 2.7 NCT00195702
- 1.5 vs 2.4 NCT00870467
- 3 vs 5.7 NCT00195663
- 1.3 vs 5.7 NCT00195663
- 0.7 vs 6.2 NCT00195702
- 0.1 vs 4.8 NCT00195702
- 0.3 vs 1.3 NCT00195702
- 2.6 vs 6.2 NCT00195702
- 1.2 vs 4.8 NCT00195702
- 0.6 vs 1.3 NCT00195702
- 5.5 vs 10.4 NCT00195663
- 1.9 vs 10.4 NCT00195663
- 0.0 vs 2.2 NCT01162421
- 0.2 vs 1.6 NCT01162421
- 0.0 vs 0.9 NCT01162421
- infliximab
- —Not posted · NCT01217086
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
13 other shared endpoints and safety
Coverage. adalimumab: 17 of 17 rows · infliximab: 17 of 17 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | adalimumab Rows use multiple source trials | infliximab Rows use multiple source trials |
|---|---|---|
| ACR20 responder rate · % of participants No placebo or comparator arm | 79.6% (n=98) @ 26wk20 mg MTXa,b,c,d NCT01185301 · Phase 3 · registry result, not featured evidence · combination show 3 more doses76.8% (n=99) @ 26wk10 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 74% (n=100) @ 26wk5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 67.3% (n=98) @ 26wk2.5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination | 35.5% (n=197) @ 26wk3 mg/kgb,c,d NCT00714493 · Phase 4 · registry result, not featured evidence 2 other source trials63.46% (n=104) @ 26wk NCT00896168 · Phase 4 · registry result, not featured evidence · combination 76.15% (n=130) @ 26wk NCT00896168 · Phase 4 · registry result, not featured evidence · combination |
| ACR50 responder rate · % of participants No placebo or comparator arm | 62.2% (n=98) @ 26wk20 mg MTXa,b,c NCT01185301 · Phase 3 · registry result, not featured evidence · combination show 3 more doses53.5% (n=99) @ 26wk10 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 51% (n=100) @ 26wk5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 45.9% (n=98) @ 26wk2.5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination | 47.12% (n=104) @ 26wka,b,c NCT00896168 · Phase 4 · registry result, not featured evidence · combination show 1 more dose57.69% (n=130) @ 26wk NCT00896168 · Phase 4 · registry result, not featured evidence · combination |
| ACR70 responder rate · % of participants No placebo or comparator arm | 45.9% (n=98) @ 26wk20 mg MTXa,b,c NCT01185301 · Phase 3 · registry result, not featured evidence · combination show 3 more doses41.4% (n=99) @ 26wk10 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 34% (n=100) @ 26wk5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 24.5% (n=98) @ 26wk2.5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination | 29.81% (n=104) @ 26wka,b,c NCT00896168 · Phase 4 · registry result, not featured evidence · combination show 1 more dose29.23% (n=130) @ 26wk NCT00896168 · Phase 4 · registry result, not featured evidence · combination |
| DAS28 absolute change · score No placebo or comparator arm | -2.2 score @ 48wka,e,c,d,f NCT01752855 · Phase 2 · registry result, not featured evidence show 1 more dose-2.4 score @ 48wk NCT01752855 · Phase 2 · registry result, not featured evidence | -2.8 score @ 54wk10 mg/kga,e,c,d,f NCT00691028 · Phase 3 · registry result, not featured evidence show 2 more doses-2.57 score @ 54wk6 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence -2.3 score @ 54wk3 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence |
| DAS28-CRP absolute change · score | -2.3 vs -1.4 Standard of Care score @ 26wkg,c,d NCT01162421 · Phase 4 · registry result, not featured evidence | -2.199 vs -2.317 Remicade US score @ 26wka,g,c,d NCT02990806 · Phase 3 · registry result, not featured evidence show 1 more dose-2.192 vs -2.317 Remicade US score @ 26wk NCT02990806 · Phase 3 · registry result, not featured evidence |
| DAS28-ESR absolute change · score | -2.8 vs -1.8 placebo score @ 26wkc,d NCT00870467 · Phase 3 · registry result, not featured evidence | -2.387 vs -2.533 Remicade US score @ 26wka,c,d NCT02990806 · Phase 3 · registry result, not featured evidence show 1 more dose-2.375 vs -2.533 Remicade US score @ 26wk NCT02990806 · Phase 3 · registry result, not featured evidence |
| HAQ-DI absolute change · score No placebo or comparator arm | -0.82 score @ 26wk20 mg MTXa,b,c,d NCT01185301 · Phase 3 · registry result, not featured evidence · combination show 3 more doses-0.78 score @ 26wk10 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination -0.71 score @ 26wk5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination -0.72 score @ 26wk2.5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination | -0.223 score @ 26wk3 mg/kgb,c,d NCT00714493 · Phase 4 · registry result, not featured evidence 2 other source trials-0.59 score @ 26wk NCT00896168 · Phase 4 · registry result, not featured evidence · combination -0.83 score @ 26wk NCT00896168 · Phase 4 · registry result, not featured evidence · combination |
| Modified Sharp absolute change · score No placebo or comparator arm | 1.6 score @ 52wka,c,d,h NCT00870467 · Phase 3 · registry result, not featured evidence show 1 more dose9.6 score @ 52wk NCT00870467 · Phase 3 · registry result, not featured evidence | 0 score @ 54wk10 mg/kga,c,d,h NCT00691028 · Phase 3 · registry result, not featured evidence show 2 more doses0.48 score @ 54wk6 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence 0 score @ 54wk3 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence |
| Morning Stiffness Duration absolute change · minutes No placebo or comparator arm | 30 minutes @ 204wk40 mg every other weekb,c,d,i NCT00235872 · Phase 3 · registry result, not featured evidence | -36.63 minutes @ 26wka,b,c,d,i NCT00896168 · Phase 4 · registry result, not featured evidence · combination show 1 more dose-77.12 minutes @ 26wk NCT00896168 · Phase 4 · registry result, not featured evidence · combination |
| Pain VAS absolute change · score No placebo or comparator arm | -7 score @ 264wk40 mg Eowj,c,d,k NCT00235833 · Phase 2 · registry result, not featured evidence | -26.8 score @ 26wka,j,c,d,k NCT00896168 · Phase 4 · registry result, not featured evidence · combination show 1 more dose-37.3 score @ 26wk NCT00896168 · Phase 4 · registry result, not featured evidence · combination |
| Patient Global Assessment absolute change · score No placebo or comparator arm | -19.5 score @ 264wk40 mg Eowj,c,d,k NCT00235833 · Phase 2 · registry result, not featured evidence | -28.3 score @ 26wka,j,c,d,k NCT00896168 · Phase 4 · registry result, not featured evidence · combination show 1 more dose-39.3 score @ 26wk NCT00896168 · Phase 4 · registry result, not featured evidence · combination |
| Physician Global Assessment absolute change · score No placebo or comparator arm | -35.5 score @ 264wk40 mg Eowj,c,d,k NCT00235833 · Phase 2 · registry result, not featured evidence | -25.3 score @ 26wka,j,c,d,k NCT00896168 · Phase 4 · registry result, not featured evidence · combination show 1 more dose-36.4 score @ 26wk NCT00896168 · Phase 4 · registry result, not featured evidence · combination |
| RAMRIS Synovitis absolute change · score | -3.38 vs -3.88 placebo score @ 78wka,l,c,d,m NCT00420927 · Phase 4 · registry result, not featured evidence · combination show 1 more dose-3.25 vs -3.88 placebo score @ 78wk NCT00420927 · Phase 4 · registry result, not featured evidence · combination | -2.3 vs 0.24 placebo score @ 14wkl,c,d,m NCT01313520 · Phase 2 · registry result, not featured evidence |
| Dropout rate | 23.2%40 mg every other weekn NCT00195702 · Phase 3 show 50 more results—40 mg every other week NCT00195702 · Phase 3 20.8%20 mg weekly NCT00195702 · Phase 3 —20 mg weekly, then 40 mg every other week NCT00195702 · Phase 3 —maximum tolerated dose NCT03505008 · Phase 4 · registry result, not featured evidence · combination —reduced dose NCT03505008 · Phase 4 · registry result, not featured evidence · combination 24.8%40 mg Eow NCT02198651 · Phase 4 · registry result, not featured evidence —40 mg Eow NCT02198651 · Phase 4 · registry result, not featured evidence —Adalimumab Tapering NCT02198651 · Phase 4 · registry result, not featured evidence 66.7% NCT02451748 · Phase 4 · registry result, not featured evidence · combination — NCT01500278 · Phase 4 · registry result, not featured evidence · combination 32.5% NCT01162421 · Phase 4 · registry result, not featured evidence 10.3%high dose NCT01185288 · Phase 4 · registry result, not featured evidence · combination 12.3%low dose NCT01185288 · Phase 4 · registry result, not featured evidence · combination —ADA+MTX/ADA+MTX (Arm 2) NCT00420927 · Phase 4 · registry result, not featured evidence · combination —ADA+MTX/OL ADA+MTX (Arm 3) NCT00420927 · Phase 4 · registry result, not featured evidence · combination 5.9% NCT03172325 · Phase 3 · registry result, not featured evidence 9.2%20 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 6.1%10 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 7%5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 15.3%2.5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 39.4%Adalimumab NCT00195663 · Phase 3 · registry result, not featured evidence 26.9%Adalimumab + Methotrexate NCT00195663 · Phase 3 · registry result, not featured evidence · combination 36% NCT00690573 · Phase 3 · registry result, not featured evidence 9.4%DB Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence —DB Adalimumab/OL Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence —DB Adalimumab/RE OL Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence 62.1% NCT00195650 · Phase 3 · registry result, not featured evidence 5%40 mg/0.8 mL NCT01231321 · Phase 3 · registry result, not featured evidence 8.2%40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence —40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence —40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence 11.2%80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence —80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence —80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence 22.7%40 mg or 80 mg every other week NCT00603993 · Phase 3 · registry result, not featured evidence 47.6%40 mg every other week NCT00235872 · Phase 3 · registry result, not featured evidence 1.7%40 mg NCT00538902 · Phase 2/3 · registry result, not featured evidence —40 mg EOW NCT00538902 · Phase 2/3 · registry result, not featured evidence 4.1%80 mg NCT00538902 · Phase 2/3 · registry result, not featured evidence —80 mg EOW NCT00538902 · Phase 2/3 · registry result, not featured evidence 0%Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence —Period 1: Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence —Period 2: Adalimumab / Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence 2%40 mg NCT02565810 · Phase 2 · registry result, not featured evidence 9.1%Current Formulation for 24 Weeks, NCT01752855 · Phase 2 · registry result, not featured evidence 2.3%New Formulation for 48 Weeks NCT01752855 · Phase 2 · registry result, not featured evidence 2%40 mg every other week NCT01712178 · Phase 2 · registry result, not featured evidence —Current Formulation Adalimumab NCT01561313 · Phase 2 · registry result, not featured evidence —New Formulation of Adalimumab NCT01561313 · Phase 2 · registry result, not featured evidence 64%40 mg Eow NCT00235833 · Phase 2 · registry result, not featured evidence | —Infliximab + Methotrexate (Moderatn NCT00896168 · Phase 4 · registry result, not featured evidence · combination show 13 more results14.6%Infliximab + Methotrexate (Severe NCT00896168 · Phase 4 · registry result, not featured evidence · combination —Stage 1, 2 and 3: NI-071 Group NCT02990806 · Phase 3 · registry result, not featured evidence —Stage 2 and Stage 3: Remicade US t NCT02990806 · Phase 3 · registry result, not featured evidence 38% NCT00732875 · Phase 3 · registry result, not featured evidence · combination —10 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence —10 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence —6 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence —6 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence —3 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence —3 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence 6.1%Open-label NCT00691028 · Phase 3 · registry result, not featured evidence 0% NCT01313520 · Phase 2 · registry result, not featured evidence 10% NCT00948610 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | —40 mg every other weekn NCT00195702 · Phase 3 show 50 more results—40 mg every other week NCT00195702 · Phase 3 —20 mg weekly NCT00195702 · Phase 3 —20 mg weekly, then 40 mg every other week NCT00195702 · Phase 3 —maximum tolerated dose NCT03505008 · Phase 4 · registry result, not featured evidence · combination —reduced dose NCT03505008 · Phase 4 · registry result, not featured evidence · combination 1.3%40 mg Eow NCT02198651 · Phase 4 · registry result, not featured evidence —40 mg Eow NCT02198651 · Phase 4 · registry result, not featured evidence —Adalimumab Tapering NCT02198651 · Phase 4 · registry result, not featured evidence — NCT02451748 · Phase 4 · registry result, not featured evidence · combination — NCT01500278 · Phase 4 · registry result, not featured evidence · combination 12.5% NCT01162421 · Phase 4 · registry result, not featured evidence 3.9%high dose NCT01185288 · Phase 4 · registry result, not featured evidence · combination 4.5%low dose NCT01185288 · Phase 4 · registry result, not featured evidence · combination —ADA+MTX/ADA+MTX (Arm 2) NCT00420927 · Phase 4 · registry result, not featured evidence · combination —ADA+MTX/OL ADA+MTX (Arm 3) NCT00420927 · Phase 4 · registry result, not featured evidence · combination 2.9% NCT03172325 · Phase 3 · registry result, not featured evidence 3.1%20 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 2%10 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 0%5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 3.1%2.5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 9.9%Adalimumab NCT00195663 · Phase 3 · registry result, not featured evidence 11.9%Adalimumab + Methotrexate NCT00195663 · Phase 3 · registry result, not featured evidence · combination — NCT00690573 · Phase 3 · registry result, not featured evidence —DB Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence —DB Adalimumab/OL Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence —DB Adalimumab/RE OL Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence 22.9% NCT00195650 · Phase 3 · registry result, not featured evidence 3%40 mg/0.8 mL NCT01231321 · Phase 3 · registry result, not featured evidence 4.4%40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence —40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence —40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence 3.4%80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence —80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence —80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence —40 mg or 80 mg every other week NCT00603993 · Phase 3 · registry result, not featured evidence 11%40 mg every other week NCT00235872 · Phase 3 · registry result, not featured evidence 1.7%40 mg NCT00538902 · Phase 2/3 · registry result, not featured evidence —40 mg EOW NCT00538902 · Phase 2/3 · registry result, not featured evidence 2.5%80 mg NCT00538902 · Phase 2/3 · registry result, not featured evidence —80 mg EOW NCT00538902 · Phase 2/3 · registry result, not featured evidence —Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence —Period 1: Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence —Period 2: Adalimumab / Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence —40 mg NCT02565810 · Phase 2 · registry result, not featured evidence 0%Current Formulation for 24 Weeks, NCT01752855 · Phase 2 · registry result, not featured evidence 2.3%New Formulation for 48 Weeks NCT01752855 · Phase 2 · registry result, not featured evidence 2%40 mg every other week NCT01712178 · Phase 2 · registry result, not featured evidence —Current Formulation Adalimumab NCT01561313 · Phase 2 · registry result, not featured evidence —New Formulation of Adalimumab NCT01561313 · Phase 2 · registry result, not featured evidence —40 mg Eow NCT00235833 · Phase 2 · registry result, not featured evidence | —Infliximab + Methotrexate (Moderatn NCT00896168 · Phase 4 · registry result, not featured evidence · combination show 13 more results5.4%Infliximab + Methotrexate (Severe NCT00896168 · Phase 4 · registry result, not featured evidence · combination —Stage 1, 2 and 3: NI-071 Group NCT02990806 · Phase 3 · registry result, not featured evidence —Stage 2 and Stage 3: Remicade US t NCT02990806 · Phase 3 · registry result, not featured evidence 17.4% NCT00732875 · Phase 3 · registry result, not featured evidence · combination —10 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence —10 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence —6 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence —6 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence —3 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence —3 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence 4.9%Open-label NCT00691028 · Phase 3 · registry result, not featured evidence — NCT01313520 · Phase 2 · registry result, not featured evidence — NCT00948610 · Phase na · registry result, not featured evidence |
| Serious AEs | 13%40 mg every other weekn NCT00195702 · Phase 3 show 50 more results—40 mg every other week NCT00195702 · Phase 3 16%20 mg weekly NCT00195702 · Phase 3 —20 mg weekly, then 40 mg every other week NCT00195702 · Phase 3 7.4%maximum tolerated dose NCT03505008 · Phase 4 · registry result, not featured evidence · combination 4.5%reduced dose NCT03505008 · Phase 4 · registry result, not featured evidence · combination 2.7%40 mg Eow NCT02198651 · Phase 4 · registry result, not featured evidence 7.7%40 mg Eow NCT02198651 · Phase 4 · registry result, not featured evidence 1%Adalimumab Tapering NCT02198651 · Phase 4 · registry result, not featured evidence 0% NCT02451748 · Phase 4 · registry result, not featured evidence · combination 13% NCT01500278 · Phase 4 · registry result, not featured evidence · combination 10.3% NCT01162421 · Phase 4 · registry result, not featured evidence 7.1%high dose NCT01185288 · Phase 4 · registry result, not featured evidence · combination 3.9%low dose NCT01185288 · Phase 4 · registry result, not featured evidence · combination 11.4%ADA+MTX/ADA+MTX (Arm 2) NCT00420927 · Phase 4 · registry result, not featured evidence · combination 6.9%ADA+MTX/OL ADA+MTX (Arm 3) NCT00420927 · Phase 4 · registry result, not featured evidence · combination 2.9% NCT03172325 · Phase 3 · registry result, not featured evidence 7.1%20 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 3%10 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 2%5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 5.1%2.5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 23.7%Adalimumab NCT00195663 · Phase 3 · registry result, not featured evidence 20.9%Adalimumab + Methotrexate NCT00195663 · Phase 3 · registry result, not featured evidence · combination 24% NCT00690573 · Phase 3 · registry result, not featured evidence 4.1%DB Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence —DB Adalimumab/OL Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence —DB Adalimumab/RE OL Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence 51.1% NCT00195650 · Phase 3 · registry result, not featured evidence 1%40 mg/0.8 mL NCT01231321 · Phase 3 · registry result, not featured evidence —40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence 4.9%40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence 3.3%40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence —80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence 6.4%80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence 1.9%80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence 22.7%40 mg or 80 mg every other week NCT00603993 · Phase 3 · registry result, not featured evidence 35.9%40 mg every other week NCT00235872 · Phase 3 · registry result, not featured evidence —40 mg NCT00538902 · Phase 2/3 · registry result, not featured evidence 0%40 mg EOW NCT00538902 · Phase 2/3 · registry result, not featured evidence —80 mg NCT00538902 · Phase 2/3 · registry result, not featured evidence 2.5%80 mg EOW NCT00538902 · Phase 2/3 · registry result, not featured evidence —Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence 0%Period 1: Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence 12.5%Period 2: Adalimumab / Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence 0%40 mg NCT02565810 · Phase 2 · registry result, not featured evidence 2.3%Current Formulation for 24 Weeks, NCT01752855 · Phase 2 · registry result, not featured evidence 4.5%New Formulation for 48 Weeks NCT01752855 · Phase 2 · registry result, not featured evidence 0%40 mg every other week NCT01712178 · Phase 2 · registry result, not featured evidence 0%Current Formulation Adalimumab NCT01561313 · Phase 2 · registry result, not featured evidence 0%New Formulation of Adalimumab NCT01561313 · Phase 2 · registry result, not featured evidence 40%40 mg Eow NCT00235833 · Phase 2 · registry result, not featured evidence | 1.9%Infliximab + Methotrexate (Moderatn NCT00896168 · Phase 4 · registry result, not featured evidence · combination show 13 more results1.5%Infliximab + Methotrexate (Severe NCT00896168 · Phase 4 · registry result, not featured evidence · combination 8.4%Stage 1, 2 and 3: NI-071 Group NCT02990806 · Phase 3 · registry result, not featured evidence 6.6%Stage 2 and Stage 3: Remicade US t NCT02990806 · Phase 3 · registry result, not featured evidence 13% NCT00732875 · Phase 3 · registry result, not featured evidence · combination —10 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence 8.7%10 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence —6 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence 4.8%6 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence —3 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence 7.1%3 mg/kg NCT00691028 · Phase 3 · registry result, not featured evidence 5.2%Open-label NCT00691028 · Phase 3 · registry result, not featured evidence 0% NCT01313520 · Phase 2 · registry result, not featured evidence 0% NCT00948610 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | 40 mg every other weekn injection site pain 17.9% (placebo 21.5%) upper respiratory tract infection 16.9% (placebo 11%) headache 11.6% (placebo 5%) NCT00195702 · Phase 3 show 40 more results20 mg weekly injection site pain 17.5% (placebo 21.5%) upper respiratory tract infection 16.5% (placebo 11%) headache 13.2% (placebo 5%) NCT00195702 · Phase 3 maximum tolerated dose liver function test abnormal 8.8% abdominal pain upper 2.9% dry mouth 1.5% NCT03505008 · Phase 4 · registry result, not featured evidence · combination reduced dose dry mouth 3% alanine aminotransferase increased 1.5% cough 1.5% NCT03505008 · Phase 4 · registry result, not featured evidence · combination 40 mg Eow cough 2.7% (placebo 5%) nasopharyngitis 2.7% (placebo 20%) urinary tract infection 1.4% (placebo 0%) NCT02198651 · Phase 4 · registry result, not featured evidence 40 mg Eow nasopharyngitis 10.3% (placebo 20%) upper respiratory tract infection 7.7% (placebo 0%) hepatic enzyme increased 5.1% (placebo 0%) NCT02198651 · Phase 4 · registry result, not featured evidence nasopharyngitis 15.7% (placebo 20%) arthralgia 5.9% (placebo 0%) influenza 4.9% (placebo 10%) NCT02198651 · Phase 4 · registry result, not featured evidence nasopharyngitis 15.3% headache 10.7% upper respiratory tract infection 10.3% NCT01500278 · Phase 4 · registry result, not featured evidence · combination rheumatoid arthritis 25.6% nasopharyngitis 20.5% alanine aminotransferase increased 15.4% NCT01162421 · Phase 4 · registry result, not featured evidence high dose nausea 10.3% upper respiratory tract infection 7.7% urinary tract infection 7.1% NCT01185288 · Phase 4 · registry result, not featured evidence · combination low dose nausea 9.7% fatigue 9.1% upper respiratory tract infection 9.1% NCT01185288 · Phase 4 · registry result, not featured evidence · combination cough 6.7% (placebo 3.6%) influenza 5.7% (placebo 2.7%) nasopharyngitis 5.7% (placebo 3.6%) NCT00420927 · Phase 4 · registry result, not featured evidence · combination upper respiratory tract infection 11.2% (placebo 6.3%) nasopharyngitis 8.9% (placebo 3.6%) alanine aminotransferase increased 6.2% (placebo 2.7%) NCT00420927 · Phase 4 · registry result, not featured evidence · combination injection site reaction 8.8% headache 5.9% nausea 5.9% NCT03172325 · Phase 3 · registry result, not featured evidence 20 mg MTX nasopharyngitis 11.2% headache 9.2% alopecia 8.2% NCT01185301 · Phase 3 · registry result, not featured evidence · combination 10 mg MTX nausea 13.1% alopecia 6.1% diarrhoea 6.1% NCT01185301 · Phase 3 · registry result, not featured evidence · combination 5 mg MTX diarrhoea 6% headache 6% nasopharyngitis 6% NCT01185301 · Phase 3 · registry result, not featured evidence · combination 2.5 mg MTX nausea 7.1% arthralgia 6.1% abdominal pain upper 4.1% NCT01185301 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 22.6% headache 21.5% nausea 17.5% NCT00195663 · Phase 3 · registry result, not featured evidence nasopharyngitis 30.2% headache 20.5% upper respiratory tract infection 18.7% NCT00195663 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 56% upper respiratory tract infection 56% influenza 32% NCT00690573 · Phase 3 · registry result, not featured evidence nasopharyngitis 15.2% (placebo 16.6%) hepatic function abnormal 8.2% (placebo 5.5%) alanine aminotransferase increased 7.6% (placebo 3.7%) NCT00870467 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 46.3% rheumatoid arthritis 25.4% sinusitis 24.9% NCT00195650 · Phase 3 · registry result, not featured evidence 40 mg/0.8 mL nasopharyngitis 4% respiratory disorder 4% headache 3% NCT01231321 · Phase 3 · registry result, not featured evidence 40 mg every other week nausea 5.5% (placebo 5.3%) headache 4.9% (placebo 5.3%) nasopharyngitis 4.9% (placebo 5.3%) NCT00647270 · Phase 3 · registry result, not featured evidence 40 mg every other week nasopharyngitis 6.6% (placebo 5.3%) upper respiratory tract infection 2.6% (placebo 7%) cough 0% (placebo 5.3%) NCT00647270 · Phase 3 · registry result, not featured evidence 80 mg monthly upper respiratory tract infection 3.2% (placebo 7%) nasopharyngitis 2.7% (placebo 5.3%) cough 0% (placebo 5.3%) NCT00647270 · Phase 3 · registry result, not featured evidence 80 mg monthly nausea 6.2% (placebo 5.3%) upper respiratory tract infection 5.2% (placebo 7%) headache 4.7% (placebo 5.3%) NCT00647270 · Phase 3 · registry result, not featured evidence 40 mg or 80 mg every other week nasopharyngitis 60.2% adverse drug reaction 29.5% antinuclear antibody positive 15.9% NCT00603993 · Phase 3 · registry result, not featured evidence 40 mg every other week nasopharyngitis 45% adverse drug reaction 23.6% dna antibody positive 16.2% NCT00235872 · Phase 3 · registry result, not featured evidence 40 mg EOW upper respiratory tract infection 14% (placebo 11.7%) injection site pruritus 5.8% (placebo 0%) nasopharyngitis 5.8% (placebo 6.7%) NCT00538902 · Phase 2/3 · registry result, not featured evidence 80 mg EOW upper respiratory tract infection 12.4% (placebo 11.7%) nasopharyngitis 7.4% (placebo 6.7%) injection site pruritus 4.1% (placebo 0%) NCT00538902 · Phase 2/3 · registry result, not featured evidence urinary tract infection 11.8% abdominal discomfort 5.9% arthralgia 5.9% NCT03823391 · Phase 2 · registry result, not featured evidence nasopharyngitis 12.5% bronchitis 6.3% drug hypersensitivity 6.3% NCT03823391 · Phase 2 · registry result, not featured evidence nasopharyngitis 15.9% rheumatoid arthritis 9.1% upper respiratory tract infection 9.1% NCT01752855 · Phase 2 · registry result, not featured evidence nasopharyngitis 13.6% cystitis 9.1% upper respiratory tract infection 9.1% NCT01752855 · Phase 2 · registry result, not featured evidence 40 mg every other week nasopharyngitis 10% cystitis 8% nausea 8% NCT01712178 · Phase 2 · registry result, not featured evidence pharyngitis 1.6% rash erythematous 1.6% protein urine present 0% NCT01561313 · Phase 2 · registry result, not featured evidence protein urine present 1.6% pharyngitis 0% rash erythematous 0% NCT01561313 · Phase 2 · registry result, not featured evidence 40 mg Eow nasopharyngitis 60% diarrhoea 24% pruritus 20% NCT00235833 · Phase 2 · registry result, not featured evidence | n hepatic function disnormal 50% upper respiratory infection 27.9% fever 3.8% NCT00896168 · Phase 4 · registry result, not featured evidence · combination show 9 more resultshepatic function disnormal 37.7% upper respiratory infection 30% hypolekocytosis 10.8% NCT00896168 · Phase 4 · registry result, not featured evidence · combination nasopharyngitis 12.3% upper respiratory tract infection 10.6% headache 7% NCT02990806 · Phase 3 · registry result, not featured evidence nasopharyngitis 10.7% upper respiratory tract infection 10.2% alanine aminotransferase increased 6.6% NCT02990806 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 20.7% pruritus 12% urticaria 9.8% NCT00732875 · Phase 3 · registry result, not featured evidence · combination 10 mg/kg dna antibody positive 51.9% nasopharyngitis 28.8% antinuclear antibody positive 16.3% NCT00691028 · Phase 3 · registry result, not featured evidence 6 mg/kg dna antibody positive 55.8% nasopharyngitis 27.9% antinuclear antibody positive 14.4% NCT00691028 · Phase 3 · registry result, not featured evidence 3 mg/kg dna antibody positive 65.7% nasopharyngitis 29.3% antinuclear antibody positive 25.3% NCT00691028 · Phase 3 · registry result, not featured evidence nasopharyngitis 17.1% alanine aminotransferase increased 10.1% aspartate aminotransferase increased 6.1% NCT00691028 · Phase 3 · registry result, not featured evidence joint swelling 13.3% (placebo 19.4%) headache 6.7% (placebo 0%) palpitations 6.7% (placebo 0%) NCT01313520 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 3 versus Phase 4.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context has not been resolved for both arms.
- eTrial phases differ: Phase 2 versus Phase 3.
- fAssessment timepoints differ: 48 weeks versus 54 weeks.
- gTrial phases differ: Phase 4 versus Phase 3.
- hAssessment timepoints differ: 52 weeks versus 54 weeks.
- iAssessment timepoints differ: 204 weeks versus 26 weeks.
- jTrial phases differ: Phase 2 versus Phase 4.
- kAssessment timepoints differ: 264 weeks versus 26 weeks.
- lTrial phases differ: Phase 4 versus Phase 2.
- mAssessment timepoints differ: 78 weeks versus 14 weeks.
- nPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
adalimumab
show 15 more results
show 1 more result
show 1 more result
show 7 more results
show 1 more result
show 1 more result
show 1 more result
show 3 more results
show 4 more results
show 7 more results
+ 219 further endpoints in the CSV export.
infliximab
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 24 more results
show 5 more results
show 2 more results
show 2 more results
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab's landscape · infliximab's landscape